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Transmission of Hepatitis C Virus Through Transplanted Organs and Tissue —  
Kentucky and Massachusetts, 2011
O n September 29, 2011, the United Network for Organ 
Sharing notified C D C  of two patients who tested positive for 
hepatitis C virus (HCV) infection approximately 6 months 
after receiving kidney transplants from a deceased donor. 
Before transplantation, the donor had tested negative for HCV  
antibody by the organ procurement organization. Tissue also 
was procured from the donor for possible transplantation. The 
tissue bank performed an H C V  antibody test on the donor’s 
serum specimen that was negative and nucleic acid testing 
(NAT) that was positive, but misread as negative. Retesting 
of the donor specimen during the investigation confirmed 
the NAT results as positive. D onated tissue included 43 
musculoskeletal grafts and one cardiopulmonary patch, which 
were distributed to health-care facilities in several states. An 
investigation was initiated to 1) identify potential sources of 
the donor’s infection, 2) document the mode of transmission 
to the organ recipients, and 3) ensure timely notification 
of the implanting surgeons and testing o f tissue recipients. 
Implantation of infected H CV  tissue occurred after recognition 
of new H CV  infection in the organ transplant recipients, high­
lighting the need for rapid communication between transplant 
centers, organ procurement organizations, tissue banks, and 
public health authorities regarding suspected transplantation 
transmission events.
Donor Investigation
The donor, a middle-aged man in Kentucky, sustained a 
traumatic brain injury in March 2011 in an all-terrain vehicu­
lar incident and died 2 days later. His medical history was 
significant for schizophrenia, substance abuse, and a 5-month 
incarceration approximately 10 years before his death. The 
donor had no known history o f intravenous drug use or other 
hepatitis risk factors, according to his father at the time of organ 
procurement; however, further investigation revealed that the 
donor’s father had limited contact with his son during the 
year before his death and was unfamiliar with recent personal 
habits or behaviors.
Policies ofthe Organ Procurement and Transplantation Network 
(OPTN), the oversight entity for solid organs in the United States, 
require testing for HCV  by antibody only, whereas the Food and 
Drug Administration (FDA), which regulates human cells, tis­
sues, and cellular and tissue-based products, requires screening 
of donated tissue for HCV by both antibody and NAT (1). The 
donor’s HCV  antibody tested negative on both organ and tissue 
donor screening, but misreading of the reaction wells on testing 
led to an incorrectly reported negative HCV NAT result. Once 
this error was identified, repeat NAT was performed at the tissue 
bank and confirmed that the donor was HCV-positive at the time 
of donation. During the donor’s final hospital stay in March, he 
received six units of blood products. Pretransfusion serum from 
the donor was not available for analysis. Testing of posttransfusion 
stored serum at CDC on October 28 confirmed by NAT that 
the donor was HCV-positive with genotype 1a and a viral load 
of >69,000,000 IU/mL. Blood traceback investigation of the six 
associated blood donors to the infected donor is ongoing, and all 
remaining units from these donations have been quarantined.
Organ Transplant Investigation
In March 2011, three organs (two kidneys and the liver) 
from the donor were transplanted into three recipients at a 
local hospital in Kentucky (Figure). Both kidney recipients had
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tested negative for hepatitis C before transplant, whereas the 
liver recipient had a previous diagnosis of hepatitis C.
First kidney recipient. O n July 26, 2011, the recipient of the 
first kidney, a man aged 41 years, was noted to have elevated liver 
enzymes (aspartate aminotransferase [AST]: 161 U/L; alanine 
aminotransaminase [ALT]: 217 U/L). H C V  antibody testing 
conducted August 22 was negative. Liver function tests contin­
ued to be elevated, and HCV NAT performed September 19 
was positive.
Second kidney recipient. The recipient of the second kidney, 
a woman aged 46 years, was noted to have elevated liver function 
tests on August 25 (AST: 206 U/L, ALT: 221 U/L); H CV  NAT 
was positive September 21.
Liver recipient. The liver recipient, a man aged 51 years, 
had a history o f chronic infection with HCV, genotype 1a, 
before transplant. Liver function testing on September 7 was 
unchanged from his baseline (AST: 46 U/L, ALT: 55 U/L).
At C D C , serum specimens were tested for H C V  RNA. 
Serum collected after organ transplantation from all three 
recipients tested positive for H C V  by NAT at CD C, and all 
three H C V  strains were confirmed to be genotype 1a.
Tissue Transplant Investigation
O n September 29, the organ procurem ent organization 
notified the tissue bank of the apparent H C V  transmission 
to the kidney and liver recipients. The tissue bank informed 
health-care facilities, and a voluntary recall was begun on
September 30. The tissue bank had distributed 43 musculo­
skeletal grafts and one cardiopulmonary patch to health-care 
facilities, but names and contact information for surgeons 
who implanted these tissues were not uniformly available at 
the time of recall. C D C  telephone notification o f all surgeons 
and requests for testing o f all patients was completed on 
October 27.
The cardiopulmonary patch, the only nonmusculoskeletal 
tissue distributed, had been treated with antibiotics by the 
tissue bank according to protocol and was implanted by a 
health-care facility in Massachusetts on September 26. After the 
health-care facility was notified, the recipient underwent test­
ing. Hepatitis C antibody was negative, but NAT was positive 
at 82,000 IU/mL; the recipient’s ALT was normal (12 U/L).
The 43 distributed musculoskeletal grafts were treated chemi­
cally and by irradiation at the tissue bank, according to proto­
col. Fifteen of the musculoskeletal tissues were implanted; the 
remaining 28 were returned to the tissue bank. The 15 recipients 
of musculoskeletal tissues were recommended to receive HCV 
serologic testing and NAT immediately and again 6 months 
from the time of tissue implantation. As of December 16, initial 
test results from 14 of the musculoskeletal tissue recipients were 
known, and all were negative based on H C V  NAT.
Molecular Characterization of HCV Strains
To determine the genetic relatedness among the H CV  strains 
obtained from the donor, the two kidney recipients, the liver
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FIGURE. Investigation tim e line  a fte r in itia l report o f transm ission o f hepa titis  C v irus (HCV) from  an organ and tissue donor —  Kentucky and 
Massachusetts, 2011
A bbrev ia tions: OPO = organ procurem ent organization; NAT = nucleic acid testing; UNOS = United N etw ork for Organ Sharing.
recipient, and the cardiopulmonary patch recipient, maximum 
likelihood phylogenetic trees were created (2). These analyses 
showed that two specimens from the donor and the three speci­
mens from the kidney recipients and cardiopulmonary patch 
recipient shared identical NS5b sequences; the liver recipient 
did not share these sequences, indicating previous infection. 
Quasispecies analysis was performed on the specimens that 
shared identical NS5b sequences (3). The E1-HVR1 quasi­
species sequences from the donor, the two kidney recipients, 
and the cardiopulmonary patch recipient clustered in a single 
group, indicating their close genetic relatedness consistent with 
a common source of H C V  transmission. The donor and the 
two kidney recipients and one cardiopulmonary patch recipient 
had from two to 10 distinct E1-HVR1 sequences that shared 
from 99.7% to 100% similarity with each other.
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Editorial Note
The transmission o f H C V  associated with transplanted 
organs and minimally processed tissue has been described 
previously, but this is the first recognized H C V  transmission 
via a cardiopulmonary patch (4). Although correct reading 
of tissue donor NAT screening results would have prevented 
transmission through the tissue patch, the organ recipients still 
would have become infected because current O PT N  policies 
for organ donor screening only require H C V  serologic testing 
(1). Furthermore, positive organ donor NAT screening likely 
would have resulted in quarantine of potentially infected tissue. 
Use of NAT, in addition to anti-H CV serologic testing, has 
been proposed to decrease the risk for transmitting undetected 
H CV  infection. However, no one test can uniformly detect all 
infections, either because o f false-negative tests resulting from 
the window period, or assay-related issues, or, as described in 
this report, because of hum an error.
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What is already known on this topic?
Hepatitis C virus (HCV) transmission from antibody-negative organ 
donors has been documented previously; nucleic acid testing 
(NAT) is required for tissue donors but not for organ donors.
W hat is added by this report?
A donor transm itted HCV to tw o kidney recipients and one 
tissue recipient because o f a negative antibody test (a result of 
the w indow  period) and an incorrectly read HCV NAT result. 
Implantation of infected tissue occurred after recognition o f the 
infected organ transplant recipients, h igh lighting the need for 
more rapid methods to recognize and communicate inform a­
tion on suspected transplantation transmission.
W hat are the implications for public health practice?
HCV antibody testing alone m ight not be adequate to detect 
disease in organ donors w ith  acute infection or in recipients 
who are immunosuppressed. A real-time system for notification 
o f disease clusters in transplant recipients is needed to  prevent 
further use of tissue tha t tests positive for HCV or other 
infections. Suspected disease transmission through organ and 
tissue transplantation should be reported by clinicians to 
appropriate oversight organizations and public health authori­
ties w ithou t delay.
W ithout information regarding a donor’s behavioral risk 
factors, the assay selection and sensitivity of pretransplantation 
testing is critical. The incidence of H CV  infection not detected 
by serologic screening for anti-H CV  antibody varies from 
1 in 5,000 for normal-risk patients to 1 in 1,000 for patients at 
high risk (5). The window period (i.e., the time from exposure 
to detectable H CV  antibody) has a mean of 65—70 days; this 
period is shortened to 3—5 days with use ofNAT (6). A transplant 
facility’s decision to use an organ is based on the organ procure­
ment organization’s assessment of the donor’s risk status and on 
test results (5). Multiple factors, including the urgent need for 
a potentially life-saving transplant and informed consent of the 
transplant candidate must be considered when determining 
whether benefits of transplantation outweigh the risk for trans­
mitting HCV. The U.S. Public Health Service recently drafted 
guidelines recommending testing of all organ donors with NAT 
for H CV  regardless of risk status (7). Even if test results are not 
available at the time of transplantation, results still can be used 
afterward to guide recipient evaluation and treatment.
The diagnosis of H CV  infection in two recipients of kidneys 
from the same donor should raise immediate suspicion of donor- 
derived infection and reporting to O PTN  and to local and state 
health departments as required by policy. Reporting to local 
and state health departments also should occur because acute 
H CV  infection is a nationally notifiable disease. Reporting of 
suspected new diagnoses in organ recipients, including to tissue 
banks, should occur without delay, because such diagnoses might 
have implications for tissues that have not yet been transplanted.
The events in this report demonstrate the importance of timely 
communication once a transplant transmission is suspected and 
the difficulty of tracking tissue to the patient or provider level 
should a potential transmission be recognized after tissue has been 
distributed. Although FDA requires that the tissue bank track the 
distribution of tissues down to the institutional level, no government 
regulations require tracking tissue to the patient level; hospitals are 
asked voluntarily to return a record, often a postcard, to the tissue 
bank to notify them ofimplantation ofthe tissue. Many health-care 
facilities have a mechanism to track tissue to the patient, although 
approaches are not standardized (8). Systems that facilitate real-time 
notification of possible disease transmission to tissue banks, organ 
procurement organizations, and other transplant centers do not 
exist, and development is hindered by the lack of standardized tissue 
nomenclature and identification standards (9,10).
This investigation reveals several areas in which current detec­
tion and notification might be improved to prevent similar future 
transplant transmission events, including: 1) consideration of the 
use ofH C V  NAT for organ donors; 2) use of algorithms or other 
procedures to ensure accurate reading of test results and reduce 
human error; and 3) timely feedback ofpossible disease transmis­
sion in organ or tissue recipients to organ procurement organi­
zations, tissue banks, public health authorities, and regulators.
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Food Safety Epidemiology Capacity in State Health Departments —  
United States, 2010
In 2002, the Council of State and Territorial Epidemiologists 
(CSTE) conducted its first national food safety epidemiology 
capacity assessment (1), which provided the basis for devel­
opment of minimum performance standards to guide state 
and local foodborne disease control programs. During April 
2010, CSTE sent states a follow-up, web-based questionnaire 
to gather information about food safety-related workforce 
training and education, epidemiology and laboratory capacity, 
and information technology (IT) to support surveillance. This 
report summarizes the results o f the assessment, which found 
that in 2010, states reported a need for 304 more full-time 
equivalent (FTE) employees working in food safety to reach 
full program capacity, with the greatest demand for master’s 
degree-level epidemiologists (50% of demand). Barriers to 
investigating foodborne outbreaks reported most often by 
states included delayed notification of the outbreak (reported 
by 41 states), lack o f a sufficient number of foodborne safety 
staff members (29 states), lower prioritization of investigations 
(27 states), lack of ability to pay overtime (20 states), and 
lack of adequate epidemiology expertise (12 states). Strategies 
should be developed to increase the number of food safety staff 
members and enhance their training opportunities, address 
gaps in IT, and improve the relationship between state and 
local health departments and federal agencies collaborating 
on responses to foodborne disease outbreaks.
The main objectives of the food safety epidemiology capac­
ity assessment were to count and characterize the food safety 
workforce in local, regional, and state health departments and 
to measure and evaluate core capacity to detect, investigate, 
and respond to foodborne diseases and outbreaks. After pilot 
testing, CSTE made the assessment available online to all states 
during April 2010. The assessment was sent to the state epide­
miologist and the lead foodborne disease epidemiologist in each 
state, with a suggestion for the latter to serve as respondent. All 
50 states participated, but not every state answered all ques­
tions. Capacity was defined for participants using a qualitative 
scale,* as validated in previous CSTE assessments (2—4).
In 2010, a total of 787 FTEs were working as foodborne 
disease epidemiologists in state, regional, and local health 
departments in the United States. O f  these, 616.5 (78%) 
had an epidemiology-related degree or had completed some 
coursework in epidemiology; 170.5 (22%) had only on-the-job
* None means that none of the activity, knowledge, or resources described within 
the question were met; minimal capacity = 1% -24% , partial capacity = 
25% -49% , substantial capacity = 50%-74%, almost full capacity = 75%-99%, 
and full capacity = 100% of the activity, knowledge, or resources described 
within the question were met.
training or no formal epidemiology training (Table). Formal 
education in epidemiology was highest at the state level, 
where most (73%) foodborne disease epidemiologists had an 
epidemiology degree. The proportion o f personnel working 
as foodborne epidemiologists who had a nursing degree was 
substantially higher at the local level (19%) than at the regional 
(5%) or state (4%) level. States reported the need for an addi­
tional 304 FTEs to reach full program capacity, with the great­
est demand (50% of need) for master’s-level epidemiologists.
The number of respondents with substantial-to-full capacity 
to use electronic laboratory reporting for foodborne diseases by 
laboratory type was highest for public health laboratories and 
lower for other laboratory types (i.e., hospital-based, reference, 
and other clinical). Forty-three states reported using a National 
Electronic Diseases Surveillance System-compliant database for 
maintaining enteric illness cases. Forty-two states reported using 
an electronic database housed at the state health department for 
outbreak investigations; 13 states used an electronic database at 
the local level. All respondents used C D C ’s electronic Foodborne 
Outbreak Reporting System and National Outbreak Reporting 
System for reporting. Most states electronically recorded multiple 
variables related to cases of enteric illness, including laboratory 
results (49 states), epidemiologic risk factors (44), clinical symp­
toms (42), travel history (42), environmental exposures (42), 
food history (35), and food purchasing locales (30), as separate 
elements of their enteric illness case files.
State capacity for completing tasks related to the investiga­
tion of sporadic cases of enteric illness caused by Salmonella and 
Escherichia coli O157 varied. Nearly all (49) states entered case 
data electronically for both pathogens; other tasks were generally 
more likely to be completed for E. coli O157 than for Salmonella, 
including collection of isolates (48 and 46 states, respectively), 
pulsed-field gel electrophoresis analysis (48 and 42), analysis of 
aggregate data (46 and 45), comparison of case classification to 
standard case definition (49 and 44), interview of patients (47 
and 39), and more intensive questionnaire review (42 and 38).
Although states investigate foodborne disease outbreaks 
caused by numerous pathogens, they were more likely to inves­
tigate outbreaks associated with some pathogens than others. 
For specific pathogens, a history of investigating >75% of 
outbreaks was reported by the highest proportion o f states for 
E. coli (86% of states), followed by Listeria (81%), Salmonella 
(78%), Campylobacter (73%), other foodborne pathogens 
(68%), and norovirus (55%). Conversely, a small but sub­
stantial proportion of states reported investigating <25% of 
outbreaks caused by these same pathogens: Campylobacter
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TABLE. Level o f education or tra in ing  o f food safety ep idem io log ists, by level o f governm ent —  United States, 2010*
Level o f educa tion /tra in ing*
State R eg ion /D istric t Local Total FTEs needed to  reach fu ll capacity
No. (%) No. (%) No. (%) No. (%) No. (% increase)
Doctoral degree 14.0 (6) 7.5 (4) 8.5 (2) 30.0 (4) 25.5 (85)
Professional background 25.5 (11) 9.0 (5) 18.0 (5) 52.5 (7) 28.0 (53)
Master's degree 93.5 (39) 54.0 (32) 60.5 (16) 208.0 (26) 152.5 (73)
Bachelor's degree 15.5 (6) 11.0 (7) 13.0 (3) 39.5 (5) 26.0 (66)
Nursing degree 29.0 (12) 37.0 (22) 151.0 (40) 217.0 (28) 47.5 (22)
Some coursework 25.0 (10) 11.5 (7) 33.0 (9) 69.5 (9) 14.0 (20)
On-the-job tra ining 23.5 (10) 29.0 (17) 44.0 (12) 96.5 (12) 10.5 (11)
No form al tra in ing in ep idem io logy 14.0 (6) 10.0 (6) 50.0 (13) 74.0 (9) 0.0 —
Total 240.0 (100) 169.0 (100) 378.0 (100) 787.0 (100) 304.0 (38)
A bbrev ia tion : FTE = fu ll-tim e  equivalent employee.
* Based on responses to  an April 2010 web-based survey o f state health departm ents by the Council o f State and Territorial Epidemiologists. 
f  Doctoral degree = PhD, DrPH, or other doctoral degree in ep idem io logy; professional background = MD, DO, DVM, or DDS w ith  a dual degree in ep idem io logy; 
master's degree = MPH, MSPH, MS, or o ther master's degree in ep idem io logy; bachelor's degree = BA, BS, or o ther bachelor's degree in ep idem io logy; nursing 
degree = RN, BSN, or o ther nursing designation; some coursework = com pletion o f some coursework in ep idem io logy; on -the -job  tra in ing = receipt o f any type  o f 
on -the -job  tra in ing in epidem iology.
(16% of states), Listeria (13%), E. coli (10%), norovirus (7%) 
and Salmonella (4%) (Figure 1).
States were more likely to obtain stool specimens than food 
samples as part of foodborne outbreak investigations. Relatively 
few states reported always collecting either stool specimens 
(five states) or food (one state) samples associated with food- 
borne disease outbreaks; 33 states collected stool specimens in 
50% -99%  of outbreaks, and 36 states collected food samples 
in <50% of outbreaks. Thirty-nine states reported having 
performed 1—10 tracebacks of commercial products during 
the past 3 years; relatively few (seven states) had conducted 
>11 tracebacks, and three states completed no tracebacks of 
commercial products during that period.
All respondents reported barriers to investigating foodborne 
or enteric outbreaks. Barriers reported as either moderate 
or substantial by states included delayed notification o f  the
outbreak (reported by 41 states), lack of sufficient number of 
foodborne safety staff members (29), lower prioritization of 
investigations (27), lack of ability to pay overtime (20), lack of 
adequate epidemiology expertise (12), difficulties working with 
in-state agencies (eight), constraints related to administrative 
support (eight), and difficulties working with other state or 
federal agencies (five) (Figure 2).
In 2009, the Council to Improve Foodborne Outbreak 
Response (CIFOR) distributed to all states its Guidelines for 
Foodborne Disease Outbreak Response (5), which was intended to 
improve outbreak response. Among the states, 47 plan to read 
the document, 39 plan to distribute it, and 29 plan to review 
their practices against the recommendations in the Guidelines 
and the performance indicators therein. Few states reported 
plans to implement or incorporate the Guidelines into practice 
in the immediate future (27%).
FIGURE 1. Num ber o f states investigating outbreaks o f specific pathogens by p ropo rtion  

























* Based on responses to  an April 2010 web-based survey o f state health departm ents by the Council 
o f State and Territorial Epidemiologists.
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Editorial Note
Ensuring adequate epidemiology capacity 
in foodborne disease programs is essential for 
the timely detection, investigation, control, 
and prevention o f foodborne disease out­
breaks. Although national foodborne disease
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epidemiology and surveillance capacity has increased since the 
previous CSTE assessment (1), critical gaps remain. Levels of 
formal epidemiology education among foodborne disease epi­
demiologists, especially at the local level, were lower than those 
of the national epidemiology workforce. Foodborne diseases 
personnel at the local level, compared with those at state and 
regional/district levels, were less likely to have an epidemiology 
degree and more likely to have only on-the-job-training or no 
formal training in epidemiology (6,7); previous assessments 
show this to be particularly true of nurses working as epide­
miologists (8). States have a substantial need for additional 
FTEs, especially those with a master’s degree in epidemiology, 
to reach full capacity in foodborne diseases program capacity 
at the state, local, and regional/district levels. Many of the 
specific activities assessed in this study directly rely on having 
enough trained or competent personnel on hand to perform 
them (e.g., conducting commercial tracebacks and collection 
of stool and food specimens). Insufficient workforce capacity 
hinders the ability to conduct these activities and, therefore, 
reduces the quality and quantity o f foodborne investigations 
carried out by states.
Widespread use o f electronic surveillance systems by states 
has increased the desirability and feasibility o f electronic 
laboratory-based reporting and the potential for improving
the timeliness o f infectious disease reporting and response. 
However, improvement and investment in public health IT 
infrastructure is needed to respond adequately to foodborne 
disease outbreaks. Improvements have resulted from several 
years of federal preparedness funding targeting states’ develop­
ment of electronic surveillance and reporting systems. Despite 
these improvements, many states report that they lack core 
capacity, which has directly affected their ability to investi­
gate and control outbreaks of foodborne diseases and enteric 
illnesses. Data elements considered essential to routine surveil­
lance for foodborne diseases are collected inconsistently across 
states and some, such as food purchasing locale, are collected by 
few. States also lack adequate IT  infrastructure, based on their 
reported lack of timely notification as the single most common 
barrier to completion of foodborne disease investigations.
The findings in this report are subject to at least two limitations. 
First, state-level epidemiologists estimated current epidemiology 
capacity at regional/district and local levels. The methods 
used by responding states to estimate their own capacity were 
subjective and likely varied. Second, not all responding states 
answered every question. However, these findings still provide 
useful insight into foodborne disease epidemiology capacity 
at state and local levels.
0
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W hat is already known on this topic?
Ensuring the safety of the food supply has become a national 
public health priority, and considerable resources at the federal, 
state, and local governm ent levels have been directed at 
im proving national food safety capacity.
What is added by this report?
Data from this assessment indicate tha t overall foodborne 
disease epidem iology capacity needs to improve to  achieve full 
capacity to detect, investigate, and respond to foodborne 
disease outbreaks.
What are the implications for public health practice?
Agencies at the federal, state, and local levels should work 
together to improve capacity through increased staffing levels, 
enhanced training opportunities, and increased investment in 
health inform ation technology.
CSTE recommends an increase in the number of personnel 
working in foodborne disease epidemiology and surveillance 
in state and local health departments, and enhanced train­
ing opportunities, including use o f the CSTE/CDC applied 
epidemiology competencies (6) and the C IFO R Guidelines 
for Foodborne Disease Outbreak Response (5). Increased invest­
ment in IT  also is needed to realize greater improvements in 
foodborne disease outbreak capacity.
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Recommendations on the Use of Quadrivalent Human Papillomavirus Vaccine 
in Males — Advisory Committee on Immunization Practices (ACIP), 2011
O n October 25, 2011, the Advisory Committee on Immunization 
Practices (ACIP) recommended routine use o f quadrivalent 
human papillomavirus (HPV) vaccine (HPV4; Gardasil, Merck 
& Co. Inc.) in males aged 11 or 12 years. ACIP also recom­
mended vaccination with HPV4 for males aged 13 through 
21 years who have not been vaccinated previously or who 
have not completed the 3-dose series; males aged 22 through 
26 years may be vaccinated. These recommendations replace 
the October 2009 ACIP guidance that HPV4 may be given to 
males aged 9 through 26 years (1). For these recommendations, 
ACIP considered information on vaccine efficacy (including 
data available since October 2009, on prevention of grade 2 
or 3 anal intraepithelial neoplasia [AIN2/3], a precursor of 
anal cancer), vaccine safety, estimates o f disease and cancer 
resulting from HPV, cost-effectiveness, and programmatic con­
siderations. The evidence for HPV4 vaccination o f males was 
evaluated using Grading o f Recommendations, Assessment, 
Development, and Evaluation (GRADE) methods (2).
Background of HPV Vaccination Program in the 
United States
HPV4 is directed against HPV types 6, 11, 16, and 18, and 
was licensed by the Food and Drug Administration (FDA) for 
use in females in June 2006. Bivalent HPV  vaccine (HPV2; 
Cervarix, GlaxoSmithKline) is directed against H PV 16 and 
18, and was licensed for use in females in October 2009. 
ACIP recommends either vaccine for routine use in females 
aged 11 or 12 years (3). In 2009, HPV4 was licensed for use 
in males for prevention o f genital warts; in December 2010, 
FDA added prevention of anal cancer in males and females as 
an indication for use (4). Since 2006, HPV vaccine coverage in 
females has increased but remains low. In 2010, coverage with 
at least 1 dose among females aged 13 through 17 years was 
48.7%, and 3-dose coverage was 32.0% (5). Coverage with at 
least 1 dose among males aged 13 through 17 years was <2%.
Burden of Disease and Cancer in Males
HPV-associated cancers in males include some anal, penile, 
and oropharyngeal cancers caused primarily by H PV  16 (6—9). 
An estimated 22,000 HPV 16- and 18-associated cancers occur 
annually in the United States, including an estimated 7,000 
HPV 16- and 18-associated cancers in males (9). Data from 
U.S. cancer registries have shown increases in the incidence 
of oropharyngeal and anal cancers in men (8,9); an evaluation 
of data from 1973—2007 found increases of 1% per year for 
oropharyngeal cancers and 3% per year for anal cancers (9).
Nononcogenic H PV  types, primarily 6 and 11, cause >90% 
o f genital warts (condylomata) and most cases o f recurrent 
respiratory papillomatosis. Approximately 250,000 cases of 
genital warts occur each year in the United States among sexu­
ally active males (10,11).
Efficacy
In a phase III efficacy trial, HPV4 had high efficacy for pre­
vention o f genital warts among 4,055 males aged 16 through 
26 years. Exclusion criteria included history of genital warts, 
history o f genital lesions possibly HPV-related, and less than 
one or more than five lifetime sex partners. Among those who 
received all 3 vaccine doses and were seronegative at day 1 
and DNA-negative day 1 through m onth 7 to the respective 
HPV type (per protocol population), efficacy for prevention 
of H PV  6-, 11-, 16-, and 18-related genital warts was 89.3% 
(95% confidence interval [CI] = 65.3%—97.9%); efficacy for 
HPV 6- and 11-related genital warts was similar. Efficacy for 
prevention o f HPV 6-, 11-, 16- and 18-related genital warts 
among males who received at least 1 vaccine dose, regardless 
o f baseline infection or serology (intent to treat population), 
was 68.1% (CI = 48.8%—80.7%) (4). No efficacy was observed 
among males who were infected with the respective HPV 
type at baseline. Although grade 1, 2, and 3 penile/perineal/ 
perianal intraepithelial neoplasias were evaluated, too few were 
observed, and efficacy was not demonstrated (4).
A substudy o f the phase III efficacy trial included 598 
men who have sex with men (MSM), aged 16 through 26 
years; outcomes were genital warts; AIN grades 1, 2, or 3 
(AIN1/2/3); and AIN2/3. Per protocol efficacy for preven­
tion of H PV 6-, 11-, 16-, and 18-related genital warts was 
88.1% (CI = 13.9% -99.7% ) (Carlos Sattler, M D, Merck, 
personal communication, August 2011). Per protocol efficacy 
for prevention o f H PV  6-, 11-, 16-, 18- related AIN1/2/3 
was 77.5% (CI = 39.6% -93.3% ), and against AIN2/3 was 
74.9% (CI = 8.8% -95.4% ) (Table) (4). In the intent to treat 
population, efficacy for prevention o f H PV  6-, 11-, 16-, 
and 18-related AIN 1/2/3 was 50.3% (CI = 25.7% -67.2% ), 
and prevention of H PV  6-, 11-, 16-, and 18-related AIN2/3 
was 54.2% (CI = 18.0% -75.3% ) (4). In the intent to treat 
population, efficacy for prevention of any HPV type-related 
AIN2/3 was 24.3% (CI = -13.8%—50.0%) (4). No studies have 
evaluated the efficacy o f HPV4 for prevention of recurrent 
respiratory papillomatosis or oropharyngeal cancer.
The efficacy of HPV4 for prevention of HPV-related pre- 
cancerous lesions and disease is supported further by studies
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TABLE. Efficacy o f quadriva len t HPV vaccine fo r prevention o f HPV 6-, 11-, 16-, and 18-related genita l warts, AIN1/2/3, or AIN 2/3, per protocol,* 
in males aged 16 th rough  26 years*
C ond ition
Contro l Vaccine Vaccine e fficacy
No. Cases No. Cases % (95% CI)
Genital warts 1,404 28 1,394 3 89.3 (65.3-97.9)
AIN1/2/3§ 208 24 194 5 77.5 (39.6-93.3)
AIN2/3§ 208 13 194 3 74.9 (8.8-95.4)
A bbrev ia tions: HPV = human papillomavirus; AIN = anal in traepithelia l neoplasia; CI = confidence interval.
Source: Food and Drug Adm inistration. H ighlights o f prescribing info rm ation. Gardasil (human papillom avirus quadriva lent [types 6, 11, 16 and 18]). Available at 
http://www.fda.gov/dow nloads/b io logicsbloodvaccines/vaccines/approvedproducts/ucm 111263.pdf.
* Per protocol popula tion included males w ho received all 3 vaccine doses, were seronegative at day 1 and DNA negative at day 1 through m onth 7 to  the  respective 
HPV type, w ith  case counting beginning after m onth 7. 
f  Participants were enrolled from  North America, South America, Europe, Australia, and Asia; median duration o f fo llow -up was 2.3 years for the study in all males and
2.6 years for the  study in men w ho have sex w ith  men (MSM).
§ Efficacy for AIN studied in MSM.
among females. In three trials, HPV4 had high efficacy (>98%) 
for prevention of HPV  6-, 11-, 16-, and 18-related grade 2 or 3 
cervical intraepithelial neoplasia (CIN2/3) or adenocarcinoma 
in situ (AIS), grade 2 or 3 vulvar intraepithelial neoplasia 
(VIN2/3), and grade 2 or 3 vaginal intraepithelial neoplasia 
(VaIN2/3) (12).
Immunogenicity
Data on immunogenicity in males are available from the 
phase III trial conducted among males aged 16 through 
26 years and from bridging immunogenicity studies conducted 
among males aged 9 through 15 years (4). Seroconversion was 
high for all four HPV vaccine types and postvaccination anti­
body titers were significantly higher in males aged 9 through 
15 years compared with males aged 16 through 26 years (4). 
Data from a follow-up study o f 500 boys who were in an 
immunogenicity study showed no cases of persistent infec­
tion or disease related to any o f the four H PV  vaccine types 
during 6 years of follow-up (13). The high efficacy found in 
the clinical trials in females and males to date has not allowed 
identification of a minimum protective antibody titer.
Safety
Clinical trial data in approximately 5,300 males found that 
the most common adverse events were mild or moderate, and 
were most commonly injection-site reactions (4). Headache 
and fever were the most commonly reported systemic adverse 
events in vaccine recipients and controls (4). Since licensure, 
at least 40 million doses of HPV4 have been distributed in the 
United States through September 2011. National postlicensure 
safety data indicate that HPV4 adverse events were similar to 
those from prelicensure trials (14). Postlicensure safety data 
from the Vaccine Safety Datalink study, including data from 
>600,000 HPV4 doses administered, showed no statistically 
significant increased risk for the outcomes studied, including 
Guillain-Barre syndrome, stroke, venous thromboembolism,
appendicitis, seizures, syncope, allergic reactions, and ana­
phylaxis (15). Postlicensure safety data from a manufacturer- 
sponsored study found no increased risk for outcomes such as 
anaphylaxis and venous thromboembolism; however, persons 
who were vaccinated with HPV4 were more likely to faint on 
the day they were vaccinated than another period in which 
vaccine was not administered (16). ACIP recommends that 
vaccination providers should consider observing patients for 
15 minutes after all vaccinations, including H PV vaccination.
Cost-Effectiveness
The cost-effectiveness* o f male vaccination is sensitive to a 
range of assumptions, such as vaccine efficacy, vaccine cover­
age of females, the range o f health outcomes included, and the 
effect of HPV-associated diseases on quality of life (17—20). 
Adding male vaccination to female-only vaccination becomes 
more cost-effective when all HPV-associated health outcomes 
are included in the model and vaccine coverage of females is 
low (e.g., 3-dose vaccine coverage <50% by age 12 years). 
Adding male vaccination to female-only vaccination becomes 
less cost-effective when considering scenarios such as only 
the health outcomes for which evidence o f  vaccine efficacy is 
available, when vaccine coverage o f  females is high (such as 
3-dose vaccine coverage >70% by age 12 years), if  vaccinated 
males have mostly vaccinated sex partners, and when male 
vaccination is compared with a strategy o f increased vaccine 
coverage of females (20). At the current vaccine price, adding 
male vaccination at age 12 years to a female-only vaccination
* By charter, when considering recommendations for use of a vaccine, ACIP 
members’ deliberations should include consideration o f vaccine efficacy, as well 
as cost-benefit and risk-benefit analyses. No predefined threshold for cost- 
effectiveness is considered. To ensure that economic data presented to ACIP 
and its working groups are uniform in presentation, understandable, and of 
the highest quality, lead economists and the Health Economics Research Group 
at CD C  developed Guidance for Health Economics Studies Presented to the ACIP , 
available at http://www.cdc.gov/vaccines/recs/acip/economic-studies.htm. The 
guidance specifically mandates technical review of any economic study that is 
presented to ACIP
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strategy would cost approximately $20,000—$40,000 per 
quality-adjusted life year (QALY) in the more favorable 
scenarios and approximately $75,000 to >$250,000 per QALY 
in less favorable scenarios (18—20). Vaccination of adult males 
becomes less cost-effective as age at vaccination increases, and 
models suggest the cost per QALY gained by vaccinating males 
>21 years would be approximately 2—4 times that of vaccinat­
ing males aged <18 years (21).
Special Populations
MSM are at higher risk for conditions associated with HPV 
types 6, 11, 16, and 18 than are heterosexual men; diseases 
and cancers that have a higher incidence among MSM include 
AIN, anal cancers, and genital warts (22,23). HPV4 clinical 
trial data demonstrated high efficacy for prevention o f genital 
warts, AIN 1/2/3, and AIN2/3 (4). HPV4 is not licensed for 
males aged >26 years, and no information is available on the 
efficacy for prevention of outcomes in MSM aged >26 years. 
A cost-effectiveness analysis estimated <$50,000 per QALY 
for vaccination of MSM through age 26 years, using various 
assumptions (24).
Persons infected with the hum an immunodeficiency virus 
(HIV) also have a high burden o f HPV-associated outcomes. 
Genital warts are more common and more difficult to treat in 
HIV-infected persons (25). AIN and anal cancer are common 
in HIV-infected MSM, and data suggest that effective antiret­
roviral therapy has not reduced the burden of anal cancer (26). 
One small trial in HIV-infected boys and girls found HPV4 to 
be safe and immunogenic (27), as did a study in HIV-infected 
men (28). Antibody titers to vaccine types 6 and 18 were lower 
in HIV-infected children than those observed in age-matched 
HIV-uninfected children; the clinical significance o f this is 
not known (27). Ongoing studies will evaluate the efficacy 
and duration of immune response in HIV-infected persons.
GRADE
D ata on HPV4 for males were reviewed according to 
GRADE methods (2). Factors considered in determining the 
recommendation included benefits and harms, evidence type, 
values and preferences, and health economic analysis.'!'
Rationale
Although the largest number o f HPV-associated cancers 
occur in wom en (approxim ately 15,000 H PV  16- and 
18-associated cancers each year), an estimated 7,000 HPV 
16- and 18-associated cancers occur each year in men in the 
United States. These include anal, oropharyngeal, and penile
 ̂Additional information is available at http://www.cdc.gov/vaccines/recs/acip/ 
grade/table-refs.htm.
cancers. HPV4 has high efficacy for prevention of genital warts, 
AIN1/2/3, and AIN2/3 in males. HPV4 also has high efficacy 
for prevention o f genital warts, C IN 1/2/3 or AIS, CIN2/3, 
V IN 2/3, and VaIN2/3 in females. Although data show HPV4 
prevents various outcomes, no data are available on the efficacy 
for prevention o f  oropharyngeal or penile cancers. Vaccination 
o f males would provide direct benefits and likely would reduce 
HPV 6, 11, 16, and 18 transmission, and resulting infection, 
disease, and cancers in females (through herd immunity). 
However, no clinical efficacy data demonstrating that HPV4 
prevents HPV transmission are available.
Because HPV4 is prophylactic, it would be most effective 
when given before exposure to HPV through sexual contact. 
The recommendation for vaccination at ages 11 or 12 years 
is supported by data from the efficacy trial, demonstrating 
highest efficacy in males who had no evidence of previous or 
current HPV vaccine type infection, data on sexual behavior 
in the United States, and immunogenicity studies show­
ing higher antibody titers after vaccination o f males at ages 
9 through 15 years compared with those aged 16 through 
26 years. O ther vaccines are recommended at age 11 or 12 
years, including HPV vaccine for females. The population level 
benefits decrease with increasing age at vaccination, especially 
after age 21 years.
Recommendations
ACIP recommends routine vaccination of males aged 11 or 
12 years with HPV4 administered as a 3-dose series (recom­
mendation category: A, evidence type: 2§). The vaccination 
series can be started beginning at age 9 years. Vaccination with 
HPV4 is recommended for males aged 13 through 21 years who 
have not been vaccinated previously or who have not completed 
the 3-dose series. Males aged 22 through 26 years may be vac­
cinated. Recommendations for administration and precautions 
are unchanged from previous recommendations (1).
Recommendations for Special Populations
HPV4 is not a live vaccine and can be administered to 
persons who are immunocompromised as a result o f  infec­
tion (including HIV), disease, or medications. The immune 
response and vaccine efficacy might be less than that in immu­
nocompetent persons. For immunocompromised males, ACIP 
recommends routine vaccination with HPV4 as for all males, 
and vaccination through age 26 years for those who have not 
been vaccinated previously or who have not completed the 
3-dose series.
§ Recommendation category A: recommendation that applies to all persons in an 
age or risk-based group. Evidence type 2: randomized controlled trials with 
important limitations or exceptionally strong evidence from observational studies.
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MSM are at higher risk for infection with HPV types 6, 11, 
16, and 18 and associated conditions, including genital warts 
and anal cancer. For MSM, ACIP recommends routine vac­
cination with HPV4 as for all males, and vaccination through 
age 26 years for those who have not been vaccinated previously 
or who have not completed the 3-dose series.
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Use of Hepatitis B Vaccination for Adults with Diabetes Mellitus: 
Recommendations of the Advisory Committee on Immunization Practices (ACIP)
Hepatitis B virus (HBV) causes acute and chronic infection ofthe 
liver leading to substantial morbidity and mortality. In the United 
States, since 1996, a total of 29 outbreaks of HBV infection in 
one or multiple long-term-care (LTC) facilities, including nursing 
homes and assisted-living facilities, were reported to CDC; ofthese,
25 involved adults with diabetes receiving assisted blood glucose 
monitoring (1; CDC, unpublished data, 2011). These outbreaks 
prompted the Hepatitis Vaccines Work Group o f the Advisory 
Committee on Immunization Practices (ACIP) to evaluate the 
risk for HBV infection among all adults with diagnosed diabetes. 
The Work Group reviewed HBV infection-related morbidity 
and mortality and the effectiveness o f implementing infection 
prevention and control measures. The strength of scientific evi­
dence regarding protection was evaluated using the Grading of 
Recommendations, Assessment, Development, and Evaluation 
(GRADE) methodology,* and safety, values, and cost-effectiveness 
were incorporated into a recommendation using the GRADE 
system. Based on the Work Group findings, on October 25, 2011, 
ACIP recommended that all previously unvaccinated adults aged
19 through 59 years with diabetes mellitus (type 1 and type 2) be 
vaccinated against hepatitis B as soon as possible after a diagnosis of 
diabetes is made (recommendation category A). Data on the risk for 
hepatitis B among adults aged >60 years are less robust. Therefore, 
ACIP recommended that unvaccinated adults aged >60 years with 
diabetes may be vaccinated at the discretion ofthe treating clinician 
after assessing their risk and the likelihood ofan adequate immune 
response to vaccination (recommendation category B). This report 
summarizes these recommendations and provides the rationale 
used by ACIP to inform their decision making.
Risk for HBV Infection
An estimate of the risk for HBV infection for adults with 
diabetes living in LTC facilities was not available; continuing 
outbreaks suggest that it might be substantial. The population
* Recommendation category A: a recommendation that applies to all persons in an 
age or risk-based group. Recommendation category B: a recommendation for 
individual clinical decision making. Evidence type 1: randomized controlled 
trials, or overwhelming evidence from observational studies. Evidence type 2: 
randomized controlled trials with important limitations, or exceptionally strong 
evidence from observational studies. Evidence type 3 : observational studies, or 
randomized controlled trials with notable limitations. Evidence type 4: clinical 
experience and observations, observational studies with important limitations, 
or randomized controlled trials with several major limitations. Source: Ahmed 
F, Temte JL, Campos-Outcalt D, Schunemann HJ; for the ACIP Evidence 
Based Recommendations Work Group (EBRWG). Methods for developing 
evidence-based recommendations by the Advisory Committee on Immunization 
Practices (ACIP) of the U.S. Centers for Disease Control and Prevention (CDC). 
Vaccine 2011;29 :9171-6 . A dditional inform ation about the GRADE 
methodology related to this policy is available at http://www.cdc.gov/vaccines/ 
recs/acip/grade/table-refs.htm.
risk for HBV infection among adults with diagnosed diabe­
tes was estimated from 865 confirmed cases o f acute HBV 
infection reported during 2009-2010 from eight Emerging 
Infections Program (EIP) sites constituting approximately 
17% o f the U.S. population. The analysis was restricted to 
persons aged >23 years because o f  high rates o f  vaccination 
among younger persons. In multivariate analyses that consid­
ered persons without hepatitis B-related risk behaviors (i.e., 
injection-drug use, male sex with a male, and sex with multiple 
partners), persons aged 23 through 59 years with diabetes had 
2.1 (95% confidence interval [CI] = 1.6-2.8) times the odds 
o f developing acute hepatitis B as those without diabetes; 
the odds were 1.5 (CI = 0.9-2.5) times as likely for persons 
aged >60 years. The annual incidence o f reported cases o f 
acute HBV infection among adults with diabetes was 1.8 per 
100,000 (CI = 1.5-2.2) (2). Acute HBV infection incidence 
is underestimated; an additional 10.5 new cases of infection 
likely occurred for each reported, confirmed case (3).
Data for the period 1999-2010 from the National Health and 
Nutrition Examination Survey (NHANES), a nationally rep­
resentative sample of the noninstitutionalized U.S. population, 
indicated a 60% (p<0.001) higher seroprevalence of antibody 
to hepatitis B core antigen (indicative of past or present HBV 
infection) overall among persons aged >18 years with diagnosed 
diabetes compared with those without diabetes. Stratified by 
age, the estimated prevalence ratios were 1.7 (CI = 1.3-2.2) for 
persons aged 18 through 59 years and 1.3 (CI = 1.0—1.6) for 
those aged >60 years (CDC, unpublished data, 2011).
Morbidity and Mortality
The severity ofacute HBV infection among adults ranges from 
asymptomatic to fulminant hepatitis. National viral hepatitis 
surveillance data indicate that of the 3,371 acute HBV infec­
tions reported in 2009, 47% of the 2,126 infections for which 
information was available resulted in hospitalization, and 1% o f 
the 1,900 infections for which information was available were 
fatal (3). Data from EIP for the period 2009-2010 indicated 
a higher case-fatality rate among acute HBV-infected persons 
with diagnosed diabetes compared with those without diabetes, 
although the difference was not statistically significant (5% versus 
2%, p=0.127) (2). Acute HBV infection progresses to chronic 
infection in approximately 5% of otherwise healthy adults (4), 
but is believed to be greater among older adults with diabetes (5). 
In the United States, an estimated 700,000 to 1.4 million persons 
are infected with HBV (3). Because chronic HBV infection can 
persist for decades, persons with chronic HBV infection are the
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reservoir for continuing HBV transmission. Chronic HBV infec­
tion is associated with high morbidity and mortality, leading to 
cirrhosis and liver cancer in >15% of affected adults (5).
Diabetes is associated with nonalcoholic fatty liver disease, includ­
ing its most severe form, nonalcoholic steatohepatitis. A study of 
veterans without HBV infection indicated that adults with diabetes 
have approximately twice the risk for chronic nonalcoholic liver 
disease and hepatocellular carcinoma as those without diabetes (6).
Infection Control
HBV is highly infectious and environmentally stable (5); HBV 
can be transmitted by medical equipment that is contaminated 
with blood that is not visible to the unaided eye. Percutaneous 
exposures to HBV occur as a result o f assisted monitoring o f 
blood glucose (7) and other procedures involving instruments 
or parenteral treatments shared between persons. Lapses in 
infection control during assisted blood glucose monitoring that 
have led to HBV transmission include multipatient use of finger 
stick devices designed for single-patient use and inadequate 
disinfection and cleaning o f blood glucose monitors between 
patients. Breaches have been documented in various settings, 
including LTC facilities, hospitals, community health centers, 
ambulatory surgical centers, private offices, homes, and health 
fairs (7; CDC, unpublished data, 2011). Initiatives are ongoing 
to encourage improvement in the design and labeling o f devices 
used in diabetes monitoring and care, and for greater oversight 
and training of staff responsible for providing diabetes care.'f'
Infection control guidelines for safe blood glucose monitoring 
have been available since 1990, and guidelines targeting LTC 
settings were published in 2005 (8). Since 1982, hepatitis B 
vaccination has been recommended for health-care personnel, 
including personnel exposed to blood in LTC settings, in con­
junction with meticulous attention to infection control practice 
(5,8). In addition, a recommendation for hepatitis B vaccination 
exists for persons beginning hemodialysis (5).
Hepatitis B Vaccine
Two single-antigen recom binant hepatitis B vaccines, 
Recom bivax HB (M erck & C o., Inc.) and Engerix-B 
(GlaxoSmithKline Biologicals), and one combination hepa­
titis A and hepatitis B vaccine, Twinrix (GlaxoSmithKline 
Biologicals), are available in the United States. Hepatitis B vac­
cines have been used in the United States since 1982. Extensive 
data support their safety in all age groups (5).
Hepatitis B vaccination usually consists o f 3 doses o f  vac­
cine administered intramuscularly at 0, 1, and 6 months; other 
schedules are available. At younger ages, the immune response to
 ̂Additional inform ation available at http://www.cdc.gov/injectionsafety/ 
meetings/stickingwsafety52010.html.
vaccine is similar among adults with and without diabetes. The 
proportion of adults who achieve seroprotection (>10 mIU/mL 
antibody to hepatitis B surface antigen [anti-HBs]) after receipt 
o f the 3-dose vaccine series decreases with age, obesity, smoking, 
immunosuppression, and comorbid conditions including diabetes. 
W hen the antibody responses among older adults with and with­
out diabetes are compared, the response might be reduced among 
those with diabetes. A synthesis of available literature suggests a 
protective response is achieved after completion of the hepatitis 
B vaccine series in >90%, 80%, 65%, and <40% of adults with 
diabetes lacking comorbid conditions aged <40 years, 41 through 
59 years, 60 through 69 years, and >70 years, respectively (CDC, 
unpublished data, 2011). Revaccination with 1-3 additional doses 
ofhepatitis B vaccine safely increases the proportion ofadults who 
achieve a protective level of anti-HBs (>10 mIU/mL) (5). The 
duration of protection against symptomatic and chronic HBV 
infection lasts >22 years among healthy vaccine responders (9); 
duration o f immunity among persons with diabetes is unknown.
Cost-Effectiveness
The Hepatitis Vaccines Work Group developed economic 
models that yielded age-stratified calculations (base case) o f the 
incremental cost per quality-adjusted life-year (QALY) saved 
based on vaccinating adults with diabetes against hepatitis B.§ 
The estimated cost per QALY saved was $75,100 for persons aged
20 through 59 years but increased substantially with increasing 
age. From a lifetime perspective, a one-time vaccination program 
consisting of a 3-dose series of hepatitis B vaccine, covering 10% 
of unvaccinated U.S. adults with diagnosed diabetes aged 20 
through 59 years (or approximately 528,047 persons) would be 
expected to prevent 4271 HBV infections, 467 hospitalizations, 
256 chronic cases, 33 cases of hepatocellular carcinoma, 13 liver 
transplants, and 130 deaths. Postvaccination serologic testing and 
revaccination would add considerable cost, with limited increase 
in disease protection (CDC, unpublished data, 2011).
ACIP Recommendations
On the basis ofavailable information about HBV risk, morbid­
ity and mortality, available vaccines, age at diagnosis o f  diabetes, 
and cost-effectiveness, ACIP recommends the following:
§ The Charter of ACIP states that, when considering recommendations for use 
of a vaccine, ACIP members’ deliberations should include consideration of 
vaccine efficacy as well as cost-benefit and risk-benefit analyses. No predefined 
threshold for cost-effectiveness is considered. To ensure that economic data 
presented to the C om m ittee and its W orking G roups are uniform  in 
presentation, understandable, and of the highest quality, lead economists and 
the Health Economics Research Group at CD C  developed Guidance fo r Health 
Economics Studies Presented to the Advisory Committee on Immunization Practices 
(ACIP), available at http://www.cdc.gov/vaccines/recs/acip/economic-studies. 
htm . The guidance specifically mandates technical review of any economic 
study that is presented to ACIP
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• Hepatitis B vaccination should be administered to unvaccinated 
adults with diabetes mellitus who are aged 19 through 59 years 
(recommendation category A; evidence type 2).
• H epatitis B vaccination may be adm inistered at the 
discretion o f the treating clinician to unvaccinated adults 
w ith  d iabe tes m ellitu s  w ho are aged >60 years 
(recommendation category B; evidence type 2).
Remarks
Continued efforts are needed to increase adherence to rec­
ommended infection control practice. Shared use o f blood- 
contaminated equipment increases the risk for exposure to 
bloodborne pathogens, including hepatitis C virus, human 
immunodeficiency virus, and HBV, which is highly infectious.
Administration o f  the hepatitis B vaccine series should 
be completed as soon as feasible after diabetes is diagnosed. 
Available data do not confirm an advantage to any specific 
hepatitis B vaccine, dosage, or approved schedule for adults 
with diabetes. No serologic testing or additional hepatitis B 
vaccination is recommended for adults who received a com­
plete series of hepatitis B vaccinations at any time in the past.
The hepatitis B vaccination series can be given safely to 
persons o f any age, but current hepatitis B vaccines are less 
efficacious and less cost-effective among older adults. Evidence 
for the extent of increased risk for acute HBV infection among 
persons with diabetes who are aged >60 years is less strong than 
for younger persons with diabetes. In 2008, the median age of 
diabetes diagnosis was 53 years; two thirds of adult diabetes 
diagnoses were made before age 60 years.^
Decisions to vaccinate adults with diabetes who are aged >60 
years of age should incorporate consideration of the patient’s 
likelihood of acquiring HBV infection, including the risk posed 
by an increased need for assisted blood-glucose monitoring in 
LTC facilities, the likelihood o f experiencing chronic sequelae if 
infected with HBV, and the declining immunologic responses 
to vaccines that are associated with frailty, a geriatric syndrome 
characterized by decreased physiologic reserve and increased 
vulnerability, leading to early mortality in older adults (10).
Hepatitis B vaccine may be administered during health-care 
visits scheduled for other purposes as long as minimum intervals 
between doses are observed; there is no maximum interval between 
doses that makes the hepatitis B vaccination series ineffective.
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QuickStats
FR O M  T H E  N A TIO N A L  C E N T E R  F O R  HEALTH STATISTICS
Percentage of Employed Adults* Aged 18-64 Years with Current Asthma,+ 
Skin Condition,5 or Carpal Tunnel Syndrome^ Who Were Told Their Condition 
Was Work-Related,** by Sex —  National Health Interview Survey, 2010++
80
Asthma Skin condition Carpal tunnel syndrome
Condition
* Employed adults are persons w ho had worked at a jo b  or business any tim e  in the  12 m onths before the 
in te rview  (either fu ll-tim e  or part-tim e). 
t  A dults were defined as having current asthma if they answered "yes” to  the  fo llow ing  tw o  questions: "Have 
you ever been to ld  by a doctor or other health professional tha t you had asthma?” "Do you still have asthma?”
§ Adults were defined as having a skin condition if they answered "yes” to  the  fo llow ing  question: "D uring the 
past 12 months, have you had derm atitis, eczema, or any o ther red, inflam ed skin rash?”
11 Adults were defined as having carpal tunnel syndrome if  they answered"yes” to  the fo llow ing  tw o  questions:
"Have you ever been to ld  by a doctor o r other health professional tha t you have a condition affecting the 
w rist and hand called carpal tunnel syndrome?” and "During the past 12 m onths, have you had carpal tunnel 
syndrome?”
**  Asthma was considered work-related if  a doctor or o ther health professional had to ld  the adult tha t it "was 
probably caused by your work,” "was probably made worse by your work,” or "was ever made worse by any 
jo b  you have ever had.” Skin condition and carpal tunnel syndrome were considered work-related if  a doctor 
o r o ther health professional had to ld  the  adu lt tha t the  cond ition  "was probably work-related.” 
f t  Estimates are based on household interviews o f a sample o f the civilian, noninstitutionalized U.S. population 
and are derived from  the National Health Interview  Survey sample adult com ponent. Asthma, skin condition, 
and carpal tunnel syndrome were the on ly  three conditions for w hich participants were asked if  a docto r or 
health professional had to ld  them  the  condition was probably work-related.
§§ 95% confidence interval.
In 2010, among employed adults aged 18-64 years who currently had asthma, 6.7% had been told the ir current asthma was work- 
related. Among employed adults who had a skin condition, 5.8% had been to ld the ir skin condition was work-related. Among 
employed adults who had carpal tunnel syndrome, 69.4% had been to ld the ir carpal tunnel syndrome was work-related. Men 
(61.1%) were less likely than women (73.2%) to  have been told the ir carpal tunnel syndrome was work-related. No significant 
differences by sex for either work-related current asthma or skin conditions were observed.
Source: National Health Interview Survey, 2010 data. Available at http://www.cdc.gov/nchs/nhis.htm .
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Notifiable Diseases and Mortality Tables
TABLE I. Provisional cases o f  in fre q u e n tly  reported  no tifia b le  diseases (<1,000 cases reported  du ring  the  preceding year) —  U nited States, w eek ending 









Total cases reported fo r previous years 
2010 2009 2008 2007 2006
States reporting cases 
during current week (No.)
Anthrax — 1 0 — 1 — 1 1
Arboviral d iseases^:
California serogroup virus disease 125 0 75 55 62 55 67
Eastern equine encephalitis virus disease — 4 — 10 4 4 4 8
Powassan virus disease — 14 0 8 6 2 7 1
St. Louis encephalitis virus disease — 5 0 10 12 13 9 10
Western equine encephalitis virus disease — — — — — — — —
Babesiosis 2 622 0 NN NN NN NN NN NY (2)
Botulism, total 1 106 4 112 118 145 144 165
foodborne — 8 1 7 10 17 32 20
infant 1 68 3 80 83 109 85 97 NV (1)
other (wound and unspecified) — 30 1 25 25 19 27 48
Brucellosis — 75 3 115 115 80 131 121
Chancroid — 27 1 24 28 25 23 33
Cholera — 29 0 13 10 5 7 9
Cyclosporiasis§ 1 140 1 179 141 139 93 137 FL (1)
Diphtheria — — — — — — — —
Haemophilus influenzae,* invasive disease (age <5 yrs): 
serotype b — 7 1 23 35 30 22 29
nonserotype b — 102 6 200 236 244 199 175
unknown serotype 4 226 5 223 178 163 180 179 PA (2), OH (1), MO (1)
Hansen disease§ 2 48 1 98 103 80 101 66 FL (2)
Hantavirus pulmonary syndrome§ 
Hemolytic uremic syndrome, postdiarrheal§
— 20 1 20 20 18 32 40
— 200 7 266 242 330 292 288
Influenza-associated pediatric mortality§,++ — 118 2 61 358 90 77 43
Listeriosis 8 729 19 821 851 759 808 884 NY (2), PA (2), FL (1), WA (1), CA (2)
Measles§§ — 210 1 63 71 140 43 55
Meningococcal disease, invasive^: 
A, C, Y, and W-135 175 8 280 301 330 325 318
serogroup B — 99 5 135 174 188 167 193
other serogroup — 12 0 12 23 38 35 32
unknown serogroup 2 357 12 406 482 616 550 651 TN (1), CO (1)
Novel influenza A virus infections*** — 8 0 4 43,774 2 4 NN
Plague — 2 — 2 8 3 7 17
Poliomyelitis, paralytic — — 0 — 1 — — —
Polio virus Infection, nonparalytic§ — — — — — — — NN
Psittacosis§ — 2 0 4 9 8 12 21
Q fever, total§ 2 104 3 131 113 120 171 169
acute 1 77 2 106 93 106 — — TX (1)
chronic 1 27 1 25 20 14 — — TX (1)
Rabies, human — 2 0 2 4 2 1 3
Rubella+++ — 5 0 5 3 16 12 11
Rubella, congenital syndrome — — — — 2 — — 1




— — — — — — — —
4 106 4 142 161 157 132 125 NY (2), NC (2)
Syphilis, congenital (age <1 yr)§§§ — 229 8 377 423 431 430 349
Tetanus — 9 1 26 18 19 28 41
Toxic-shock syndrome (staphylococcal)§ — 69 2 82 74 71 92 101
Trichinellosis — 9 0 7 13 39 5 15
Tularemia — 136 2 124 93 123 137 95
Typhoid fever — 305 9 467 397 449 434 353
Vancomycin-intermediate Staphylococcus aureus§ — 61 1 91 78 63 37 6
Vancomycin-resistant Staphylococcus aureus§ 
Vibriosis (noncholera Vibrio species infections)§
— — 0 2 1 — 2 1
8 707 10 846 789 588 549 NN FL (2), TX (1), AZ (1), CA (4)
Viral hemorrhagic feverw — — — 1 NN NN NN NN
Yellow fever — — — — — — — —
See Table 1 footnotes on next page.
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— : No reported cases. N: Not reportable. NN: Not Nationally Notifiable. Cum: Cumulative year-to-date counts.
* Case counts for reporting year 2011 are provisional and subject to  change. For further information on interpretation o f these data, see http://www.cdc.gov/osels/ph_surveillance/nndss/ 
phs/files/ProvisionalNationa%20NotifiableDiseasesSurveillanceData20100927.pdf. 
t  Calculated by summing the incidence counts for the current week, the 2 weeks preceding the current week, and the 2 weeks fo llow ing the current week, for a total o f 5 preceding years.
Additional information is available at http://www.cdc.gov/osels/ph_surveillance/nndss/phs/files/5yearweeklyaverage.pdf.
§ Not reportable in all states. Data from states where the condition is not reportable are excluded from this table except starting in 2007 for the arboviral diseases, STD data, TB data, and 
influenza-associated pediatric mortality, and in 2003 for SARS-CoV. Reporting exceptions are available at http://www.cdc.gov/osels/ph_surveillance/nndss/phs/infdis.htm.
1 Includes both neuroinvasive and nonneuroinvasive. Updated weekly from reports to  the Division o f Vector-Borne Infectious Diseases, National Center for Zoonotic, Vector-Borne, and 
Enteric Diseases (ArboNET Surveillance). Data for West Nile virus are available in Table II.
** Data for H. influenzae (all ages, all serotypes) are available in Table II.
t t  Updated weekly from reports to  the Influenza Division, National Center for Immunization and Respiratory Diseases. Since October 2, 2011, no influenza-associated pediatric deaths 
occurring during the 2011-12 influenza season have been reported.
§§ No measles cases were reported for the current week.
11 Data for meningococcal disease (all serogroups) are available in Table II.
*** CDC discontinued reporting o f individual confirmed and probable cases o f 2009 pandemic influenza A (H1N1) virus infections on July 24, 2009. During 2009, four cases o f human infection 
w ith novel influenza A viruses, different from the 2009 pandemic influenza A (H1N1) strain, were reported to  CDC. The four cases o f novel influenza A virus infection reported to  CDC 
during 2010, and the eight cases reported during 2011, were identified as swine influenza A (H3N2) virus and are unrelated to  the 2009 pandemic influenza A (H1N1) virus. Total case 
counts are provided by the Influenza Division, National Center for Immunization and Respiratory Diseases (NCIRD).
t t t  No rubella cases were reported for the current week.
§§§ Updated weekly from reports to  the Division o f STD Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention.
111 There was one case o f viral hemorrhagic fever reported during week 12 o f 2010. The one case report was confirmed as lassa fever. See Table II for dengue hemorrhagic fever.
TABLE I. (Continued) Provisional cases o f infrequently reported notifiable diseases (<1,000 cases reported during the preceding year) —  United States, week
ending December 17, 2011 (50th week)*
FIGURE I. Selected no tifiab le  disease reports, U n ited States, com parison o f provisional 4-week 
to ta ls  December 17, 2011, w ith  historical data
DISEASE
Giardiasis 
Hepatitis A, acute 
Hepatitis B, acute 
























* Ratio o f current 4-week tota l to  mean o f 15 4-week totals (from previous, comparable, and subsequent 4-week 
periods for the past 5 years). The po in t where the hatched area begins is based on the  mean and tw o  standard 
deviations o f these 4-week totals.
N otifiab le  D isease D a ta  Team a n d  122 C ities M o rta lity  D a ta  Team
Jennifer W ard Deborah A. Adams
W illie J. Anderson Lenee Blanton
Rosaline Dhara Diana Harris Onweh
Pearl C. Sharp Michael S. Wodajo
1714 MMWR /  December 23, 2011 /  Vol. 60 /  No. 50
M orb id ity and M orta lity Weekly Report
TABLE II. Provisional cases o f selected notifiable diseases, United States, weeks ending December 17, 2011, and December 18, 2010 (50th week)*


























United States 12,532 26,502 31,142 ,272,762 1,254,968 104 382 579 18,696 NN 43 129 388 7,939 8,663
New England 657 871 2,043 42,691 40,497 — 0 1 1 NN — 7 22 369 478
Connecticut — 227 1,557 10,107 10,843 — 0 0 — NN — 1 9 68 77
Mainet 54 58 98 2,916 2,496 — 0 0 — NN — 1 4 47 92
Massachusetts 409 433 860 21,611 20,243 — 0 0 — NN — 3 8 152 165
New Hampshire 4 57 90 2,725 2,374 — 0 1 1 NN — 1 5 61 57
Rhode Islandt 137 78 154 3,919 3,320 — 0 0 — NN — 0 1 1 18
Vermontt 53 27 84 1,413 1,221 — 0 0 — NN — 0 5 40 69
Mid. A tlantic 2,144 3,235 3,953 159,099 166,873 — 0 1 6 NN 10 15 41 809 840
New Jersey 154 538 1,003 26,687 25,428 — 0 0 — NN — 0 1 — 51
New York (Upstate) 904 713 2,099 34,844 33,387 — 0 0 — NN 5 4 15 218 213
New York City 278 1,103 1,329 48,325 62,170 — 0 0 — NN — 1 6 83 103
Pennsylvania 808 976 1,236 49,243 45,888 — 0 1 6 NN 5 9 26 508 473
E.N. Central 1,229 4,049 7,039 193,825 201,156 3 1 5 52 NN 9 32 143 2,395 2,360
Illinois 25 1,103 1,326 49,660 58,785 — 0 0 — NN — 3 26 205 331
Indiana 252 536 3,376 27,296 22,375 — 0 0 — NN — 4 14 180 279
Michigan 627 952 1,429 47,003 47,970 2 0 3 33 NN 1 6 14 330 314
Ohio 169 1,013 1,124 48,082 49,520 1 0 3 19 NN 8 11 95 1,082 458
Wisconsin 156 463 553 21,784 22,506 — 0 0 — NN — 8 61 598 978
W.N. Central 218 1,472 1,782 70,782 70,043 — 0 2 6 NN 1 17 87 1,228 1,825
Iowa 28 211 253 10,290 10,257 — 0 0 — NN — 6 19 342 390
Kansas 17 208 288 10,068 9,333 — 0 0 — NN — 0 11 41 106
Minnesota — 287 381 13,180 14,913 — 0 0 — NN — 0 4 — 391
Missouri — 529 759 26,034 25,240 — 0 0 — NN 1 5 63 502 544
Nebraskat 139 113 218 6,142 4,924 — 0 2 6 NN — 2 12 173 258
North Dakota 2 40 77 1,891 2,283 — 0 0 — NN — 0 12 28 31
South Dakota 32 63 93 3,177 3,093 — 0 0 — NN — 2 13 142 105
S. Atlantic 4,804 5,375 7,367 271,989 249,086 — 0 2 5 NN 10 21 37 1,085 1,041
Delaware 148 85 134 4,232 4,271 — 0 0 — NN — 0 1 7 9
District o f Columbia 4 107 190 5,304 5,423 — 0 0 — NN — 0 1 5 8
Florida 847 1,494 1,698 73,036 72,671 — 0 0 — NN 7 8 17 423 393
Georgia 893 1,018 2,384 49,826 42,218 — 0 0 — NN 2 5 11 258 261
Marylandt — 473 1,125 23,545 24,438 — 0 2 5 NN — 1 6 64 39
North Carolina 1,288 971 1,688 50,232 40,407 — 0 0 — NN — 0 23 62 94
South Carolinat 626 526 946 27,933 25,783 — 0 0 — NN — 2 8 126 118
Virginiat 917 659 1,576 33,766 30,112 — 0 0 — NN 1 2 8 124 100
West Virginia 81 81 121 4,115 3,763 — 0 0 — NN — 0 5 16 19
E.S. Central 1,134 1,896 3,314 92,009 88,219 — 0 0 — NN 1 7 25 424 341
Alabamat 594 546 1,566 28,008 26,050 — 0 0 — NN 1 2 7 127 180
Kentucky 298 301 2,352 15,992 13,902 — 0 0 — NN — 1 17 164 83
Mississippi — 392 696 18,580 20,678 — 0 0 — NN — 1 4 45 24
Tennesseet 242 600 754 29,429 27,589 — 0 0 — NN — 2 6 88 54
W.S. Central 715 3,386 4,329 166,314 172,517 — 0 1 8 NN 6 8 62 527 513
Arkansast 305 309 440 15,429 14,984 — 0 0 — NN — 0 2 25 33
Louisiana 311 412 1,071 22,316 27,952 — 0 1 8 NN 1 0 9 47 66
Oklahoma 99 173 850 9,190 13,408 — 0 0 — NN 2 1 34 83 86
Texast — 2,426 3,137 119,379 116,173 — 0 0 — NN 3 5 37 372 328
M ountain 169 1,751 2,279 85,349 80,298 91 295 459 14,636 NN 2 11 30 569 592
Arizona — 547 773 27,386 25,963 89 292 456 14,470 NN — 1 4 42 38
Colorado — 421 847 22,065 19,039 — 0 0 — NN — 2 12 146 132
Idahot 5 81 235 4,081 3,987 — 0 0 — NN 1 2 9 104 105
Montanat 61 64 87 3,273 2,981 — 0 2 5 NN 1 1 6 75 49
Nevadat 29 204 380 9,990 9,386 2 2 5 97 NN — 0 2 14 38
New Mexicot — 200 1,183 10,235 10,421 — 0 4 46 NN — 3 9 122 131
Utah 51 131 190 6,541 6,482 — 0 2 15 NN — 1 5 41 71
W yomingt 23 36 67 1,778 2,039 — 0 2 3 NN — 0 5 25 28
Pacific 1,462 3,964 6,559 190,704 186,279 10 83 145 3,982 NN 4 11 21 533 673
Alaska 4 110 157 5,381 5,864 — 0 0 — NN — 0 3 14 6
California 887 2,973 5,763 145,775 142,281 10 82 145 3,975 NN 2 6 15 317 362
Hawaii — 109 141 5,444 5,840 — 0 0 — NN — 0 1 1 1
Oregon 204 277 412 13,390 11,693 — 0 1 7 NN — 2 8 126 215
Washington 367 434 672 20,714 20,601 — 0 0 — NN 2 1 9 75 89
Territories
American Samoa — 0 0 — — — 0 0 — NN N 0 0 N N
C.N.M.I. — — — — — — — — — NN — — — — —
Guam — 14 44 189 905 — 0 0 — NN — 0 0 — —
Puerto Rico — 104 349 5,010 5,816 — 0 0 — NN N 0 0 N N
U.S. Virgin Islands — 16 27 642 566 — 0 0 — NN — 0 0 — —
C.N.M.I.: Commonwealth o f Northern Mariana Islands.
U: Unavailable. — : No reported cases. N: Not reportable. NN: Not Nationally Notifiable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.
* Case counts for reporting year 2011 are provisional and subject to  change. For further information on interpretation o f these data, see http://www.cdc.gov/osels/ph_surveillance/nndss/ 
phs/files/ProvisionalNationa%20NotifiableDiseasesSurveillanceData20100927.pdf. Data for TB are displayed in Table IV, which appears quarterly.
+ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
MMWR /  December 23, 2011 /  Vol. 60 /  No. 50 1715
M orb id ity and M orta lity Weekly Report
TABLE II. (Continued) Provisional cases o f selected notifiable diseases, United States, weeks ending December 17, 2011, and December 18, 2010 (50th week)*
Dengue Virus Infection*




















United States — 3 16 203 684 — 0 1 2 10
New England — 0 1 2 10 — 0 0 — —
Connecticut — 0 0 — — — 0 0 — —
Maine** — 0 0 — 6 — 0 0 — —
Massachusetts — 0 0 — — — 0 0 — —
New Hampshire — 0 0 — — — 0 0 — —
Rhode Island** — 0 0 — 1 — 0 0 — —
Vermont** — 0 1 2 3 — 0 0 — —
Mid. Atlantic — 1 6 56 222 — 0 0 — 5
New Jersey — 0 0 — 29 — 0 0 — —
New York (Upstate) — 0 1 — 31 — 0 0 — 2
New York City — 0 4 40 141 — 0 0 — 3
Pennsylvania — 0 2 16 21 — 0 0 — —
E.N. Central — 0 2 14 67 — 0 1 1 1
Illinois — 0 2 4 21 — 0 1 1 —
Indiana — 0 1 2 14 — 0 0 — —
Michigan — 0 1 2 9 — 0 0 — —
Ohio — 0 1 2 16 — 0 0 — —
Wisconsin — 0 2 4 7 — 0 0 — 1
W.N. Central — 0 2 11 33 — 0 0 — 1
Iowa — 0 1 3 2 — 0 0 — —
Kansas — 0 1 1 4 — 0 0 — —
Minnesota — 0 1 5 14 — 0 0 — —
Missouri — 0 1 1 5 — 0 0 — —
Nebraska** — 0 0 — 7 — 0 0 — —
North Dakota — 0 1 1 1 — 0 0 — —
South Dakota — 0 0 — — — 0 0 — 1
S. A tlantic — 1 8 81 237 — 0 1 1 2
Delaware — 0 2 2 — — 0 0 — —
District o f Columbia — 0 0 — — — 0 0 — —
Florida — 1 7 61 188 — 0 0 — 2
Georgia — 0 1 3 12 — 0 0 — —
Maryland** — 0 2 5 — — 0 0 — —
North Carolina — 0 1 2 8 — 0 0 — —
South Carolina** — 0 1 1 13 — 0 0 — —
Virginia** — 0 1 7 14 — 0 1 1 —
West Virginia — 0 0 — 2 — 0 0 — —
E.S. Central — 0 3 8 7 — 0 0 — —
Alabama** — 0 1 2 4 — 0 0 — —
Kentucky — 0 1 3 2 — 0 0 — —
Mississippi — 0 0 — — — 0 0 — —
Tennessee** — 0 2 3 1 — 0 0 — —
W.S. Central — 0 2 9 28 — 0 0 — 1
Arkansas** — 0 0 — — — 0 0 — 1
Louisiana — 0 1 3 4 — 0 0 — —
Oklahoma — 0 0 — 5 — 0 0 — —
Texas** — 0 1 6 19 — 0 0 — —
M ountain — 0 1 4 24 — 0 0 — —
Arizona — 0 1 2 12 — 0 0 — —
Colorado — 0 0 — — — 0 0 — —
Idaho** — 0 0 — 3 — 0 0 — —
Montana** — 0 0 — 4 — 0 0 — —
Nevada** — 0 1 1 4 — 0 0 — —
New Mexico** — 0 0 — 1 — 0 0 — —
Utah — 0 1 1 — — 0 0 — —
Wyoming** — 0 0 — — — 0 0 — —
Pacific — 0 4 18 56 — 0 0 — —
Alaska — 0 0 — 1 — 0 0 — —
California — 0 2 5 36 — 0 0 — —
Hawaii — 0 4 5 — — 0 0 — —
Oregon — 0 0 — — — 0 0 — —
Washington — 0 1 8 19 — 0 0 — —
Territories
American Samoa — 0 0 — — — 0 0 — —
C.N.M.I. — — — — — — — — — —
Guam — 0 0 — — — 0 0 — —
Puerto Rico — 23 82 1,361 10,586 — 0 3 30 237
U.S. Virgin Islands — 0 0 — — — 0 0 — —
C.N.M.I.: Commonwealth o f Northern Mariana Islands.
U: Unavailable. — : No reported cases. N: Not reportable. NN: Not Nationally Notifiable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.
* Case counts for reporting year 2011 are provisional and subject to  change. For further information on interpretation o f these data, see http://www.cdc.gov/osels/ph_surveillance/nndss/ 
phs/files/ProvisionalNationa%20NotifiableDiseasesSurveillanceData20100927.pdf. Data for TB are displayed in Table IV, which appears quarterly.
+ Updated weekly from reports to  the Division o f Vector-Borne Infectious Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases (ArboNET Surveillance).
§ Dengue Fever includes cases that meet criteria for Dengue Fever w ith hemorrhage, other clinical and unknown case classifications.
 ̂DHF includes cases that meet criteria for dengue shock syndrome (DSS), a more severe form  o f DHF.
** Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
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TABLE II. (Continued) Provisional cases o f selected notifiable diseases, United States, weeks ending December 17, 2011, and December 18, 2010 (50th week)*
Ehrlichiosis/Anaplasmosis*






























United States 4 7 109 677 629 20 13 57 772 1,726 — 2 13 105 90
New England — 0 1 4 8 2 3 28 272 117 — 0 1 2 2
Connecticut — 0 0 — — — 0 2 — 41 — 0 0 — —
Maine5 — 0 1 1 4 — 0 3 23 17 — 0 0 — —
Massachusetts — 0 0 — — — 1 18 172 — — 0 0 — —
New Hampshire — 0 1 2 3 — 0 4 22 20 — 0 1 1 2
Rhode Island5 — 0 1 1 1 1 0 15 47 37 — 0 1 1 —
Vermont5 — 0 0 — — 1 0 1 8 2 — 0 0 — —
Mid. Atlantic — 1 7 58 84 15 5 31 353 274 — 0 2 10 15
New Jersey — 0 1 — 51 — 0 2 — 74 — 0 0 — 1
New York (Upstate) — 0 7 47 26 15 3 27 299 188 — 0 2 10 11
New York City — 0 2 11 5 — 0 5 50 11 — 0 0 — —
Pennsylvania — 0 0 — 2 — 0 1 4 1 — 0 0 — 3
E.N. Central — 0 5 31 44 1 0 3 21 510 — 1 5 44 45
Illinois — 0 4 21 16 — 0 2 9 9 — 0 1 2 3
Indiana — 0 0 — — — 0 0 — — — 0 3 34 15
Michigan — 0 2 4 2 — 0 0 — 4 — 0 2 5 —
Ohio — 0 1 6 7 1 0 1 9 2 — 0 1 1 —
Wisconsin — 0 0 — 19 — 0 3 3 495 — 0 1 2 27
W.N. Central — 1 19 159 120 — 0 8 33 733 — 0 11 15 10
Iowa N 0 0 N N N 0 0 N N N 0 0 N N
Kansas — 0 2 5 6 — 0 0 — 1 — 0 1 1 —
Minnesota — 0 12 — — — 0 1 1 720 — 0 11 — —
Missouri — 1 19 152 112 — 0 7 29 12 — 0 7 13 10
Nebraska5 — 0 1 1 2 — 0 1 1 — — 0 1 1 —
North Dakota N 0 0 N N N 0 0 N N N 0 0 N N
South Dakota — 0 1 1 — — 0 1 2 — — 0 0 — —
S. A tlantic 1 2 33 240 251 2 1 8 66 64 — 0 2 13 6
Delaware — 0 2 15 17 — 0 1 1 4 — 0 0 — —
District o f Columbia N 0 0 N N N 0 0 N N N 0 0 N N
Florida — 0 3 15 8 — 0 3 10 3 — 0 0 — —
Georgia — 0 3 18 20 — 0 2 9 1 — 0 1 2 1
Maryland5 — 0 3 28 22 — 0 2 6 15 — 0 1 1 2
North Carolina — 0 17 66 99 — 0 6 20 28 — 0 0 — —
South Carolina5 — 0 1 2 5 — 0 0 — 1 — 0 1 1 —
Virginia5 1 1 13 96 77 2 0 3 20 12 — 0 1 8 3
West Virginia — 0 0 — 3 — 0 0 — — — 0 1 1 —
E.S. Central — 1 8 73 87 — 0 2 16 20 — 0 3 14 9
Alabama5 — 0 2 4 11 — 0 1 4 7 N 0 0 N N
Kentucky — 0 3 13 16 — 0 0 — — — 0 0 — 1
Mississippi — 0 1 3 3 — 0 1 1 2 — 0 0 — 1
Tennessee5 — 0 5 53 57 — 0 2 11 11 — 0 3 14 7
W.S. Central 3 0 87 112 33 — 0 9 8 8 — 0 0 — 1
Arkansas5 1 0 13 51 14 — 0 3 6 4 — 0 0 — —
Louisiana — 0 0 — 1 — 0 0 — — — 0 0 — —
Oklahoma 2 0 82 59 15 — 0 7 2 2 — 0 0 — —
Texas5 — 0 1 2 3 — 0 1 — 2 — 0 0 — 1
Mountain — 0 0 — — — 0 0 — — — 0 1 5 —
Arizona — 0 0 — — — 0 0 — — — 0 1 4 —
Colorado N 0 0 N N N 0 0 N N N 0 0 N N
Idaho5 N 0 0 N N N 0 0 N N N 0 0 N N
Montana5 N 0 0 N N N 0 0 N N N 0 0 N N
Nevada5 N 0 0 N N N 0 0 N N N 0 0 N N
New Mexico5 N 0 0 N N N 0 0 N N N 0 0 N N
Utah — 0 0 — — — 0 0 — — — 0 1 1 —
W yoming5 — 0 0 — — — 0 0 — — — 0 0 — —
Pacific — 0 1 — 2 — 0 1 3 — — 0 1 2 2
Alaska N 0 0 N N N 0 0 N N N 0 0 N N
California — 0 1 — 2 — 0 0 — — — 0 1 2 2
Hawaii N 0 0 N N N 0 0 N N N 0 0 N N
Oregon — 0 0 — — — 0 1 3 — — 0 0 — —
Washington — 0 0 — — — 0 0 — — — 0 0 — —
Territories
American Samoa N 0 0 N N N 0 0 N N N 0 0 N N
C.N.M.I. — — — — — — — — — — — — — — —
Guam N 0 0 N N N 0 0 N N N 0 0 N N
Puerto Rico N 0 0 N N N 0 0 N N N 0 0 N N
U.S. Virgin Islands — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I.: Commonwealth o f Northern Mariana Islands.
U: Unavailable. — : No reported cases. N: Not reportable. NN: Not Nationally Notifiable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.
* Case counts for reporting year 2011 are provisional and subject to  change. For further information on interpretation o f these data, see http://www.cdc.gov/osels/ph_surveillance/nndss/ 
phs/files/ProvisionalNationa%20NotifiableDiseasesSurveillanceData20100927.pdf. Data for TB are displayed in Table IV, which appears quarterly.
+ Cumulative total E. ewingii cases reported for year 2011 = 13.
§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
MMWR /  December 23, 2011 /  Vol. 60 /  No. 50 1717
M orb id ity and M orta lity Weekly Report
TABLE II. (Continued) Provisional cases o f selected notifiable diseases, United States, weeks ending December 17, 2011, and December 18, 2010 (50th week)*
Giardiasis Gonorrhea
Haemophilus influenzae, invasive* 


























United States 148 281 445 14,299 19,083 2,978 5,982 7,484 291,262 297,339 34 64 141 3,036 2,942
New England 2 27 64 1,478 1,629 73 106 206 5,196 5,381 — 4 12 209 189
Connecticut — 4 10 216 285 — 45 150 2,184 2,386 — 1 5 50 44
Maine5 1 3 10 170 220 12 5 17 249 152 — 0 2 25 13
Massachusetts — 13 29 701 709 26 47 80 2,264 2,363 — 2 6 102 93
New Hampshire — 2 8 115 153 — 2 7 121 149 — 0 2 15 12
Rhode Island5 — 1 10 66 80 35 6 16 331 273 — 0 2 10 13
Vermont5 1 3 19 210 182 — 0 8 47 58 — 0 2 7 14
Mid. A tlantic 42 54 103 2,731 3,258 473 738 916 37,113 35,702 11 14 32 697 562
New Jersey — 0 10 — 465 45 148 232 7,440 5,721 — 2 6 104 103
New York (Upstate) 30 20 72 1,146 1,140 143 114 271 5,708 5,524 4 3 18 171 152
New York City 7 16 29 818 901 67 242 314 11,119 12,067 2 3 7 167 93
Pennsylvania 5 16 29 767 752 218 255 361 12,846 12,390 5 5 11 255 214
E.N. Central 9 47 78 2,276 3,210 323 1,033 2,091 51,039 55,760 8 11 22 537 487
Illinois — 10 19 439 678 6 280 359 12,847 15,253 1 3 11 151 167
Indiana — 4 11 189 389 53 129 1,018 6,544 6,397 — 2 7 90 100
Michigan 1 10 21 491 683 183 240 499 12,207 13,229 1 1 4 67 33
Ohio 8 16 30 755 842 47 315 398 15,127 15,964 6 3 7 164 118
Wisconsin — 8 18 402 618 34 89 118 4,314 4,917 — 1 5 65 69
W.N. Central 7 21 50 1,068 2,058 31 306 372 14,912 14,486 2 2 10 146 219
Iowa 2 4 15 262 278 4 37 54 1,846 1,747 — 0 1 3 1
Kansas — 2 8 94 204 — 42 57 2,018 2,006 — 0 2 19 23
Minnesota — 0 13 — 821 — 38 56 1,820 2,064 — 0 5 — 75
Missouri 4 8 23 403 413 — 150 204 7,245 6,876 2 1 5 83 82
Nebraska5 — 3 11 166 214 25 24 51 1,249 1,147 — 0 2 26 26
North Dakota — 0 12 38 31 — 4 8 185 193 — 0 6 14 12
South Dakota 1 1 8 105 97 2 11 20 549 453 — 0 1 1 —
S. A tlantic 33 51 98 2,594 3,862 1,266 1,486 1,927 73,147 73,554 3 14 31 688 737
Delaware 1 0 3 33 34 20 15 31 781 957 — 0 2 5 5
District o f Columbia — 0 3 31 55 — 38 98 1,924 2,033 — 0 0 — 6
Florida 26 23 50 1,193 2,067 207 378 462 18,903 19,595 — 5 12 218 185
Georgia — 10 51 645 785 294 311 874 15,134 14,791 1 2 7 122 158
Maryland5 5 6 13 297 258 — 120 203 5,603 7,044 1 2 5 91 68
North Carolina N 0 0 N N 400 323 548 16,040 13,542 — 1 7 74 123
South Carolina5 — 2 8 111 142 170 152 257 7,938 7,769 — 1 5 70 80
Virginia5 1 5 32 262 474 165 111 352 6,051 7,270 1 1 8 91 82
West Virginia — 0 8 22 47 10 17 29 773 553 — 0 9 17 30
E.S. Central 1 3 9 160 216 323 515 1,007 25,225 24,116 2 3 12 199 174
Alabama5 1 3 9 160 216 174 162 408 8,583 7,616 — 1 4 47 30
Kentucky N 0 0 N N 70 77 712 4,374 3,612 1 1 4 41 36
Mississippi N 0 0 N N — 113 191 5,062 5,944 1 0 3 19 15
Tennessee5 N 0 0 N N 79 145 224 7,206 6,944 — 2 5 92 93
W.S. Central 2 5 15 250 382 211 885 1,181 43,241 48,066 5 2 26 140 136
Arkansas5 1 2 9 117 129 86 89 138 4,523 4,602 1 0 3 31 18
Louisiana 1 2 10 133 191 98 136 313 6,486 8,585 — 1 4 45 29
Oklahoma — 0 0 — 62 27 51 254 2,658 4,101 4 1 19 62 81
Texas5 N 0 0 N N — 589 839 29,574 30,778 — 0 4 2 8
M ountain 24 25 45 1,292 1,719 6 207 289 10,361 9,168 1 5 12 251 294
Arizona 2 3 6 123 161 — 80 131 4,240 3,124 — 1 6 84 108
Colorado 14 11 25 618 680 — 41 89 2,114 2,683 1 1 5 64 81
Idaho5 4 3 9 158 208 1 2 13 128 136 — 0 2 21 18
Montana5 3 2 5 79 107 — 1 4 79 99 — 0 1 3 2
Nevada5 1 1 7 74 104 3 39 103 1,900 1,668 — 0 2 17 10
New Mexico5 — 2 6 90 103 — 33 98 1,605 1,118 — 1 4 42 40
Utah — 3 9 128 303 2 5 10 255 303 — 0 3 18 29
W yoming5 — 0 5 22 53 — 0 3 40 37 — 0 1 2 6
Pacific 28 47 128 2,450 2,749 272 628 791 31,028 31,106 2 3 9 169 144
Alaska — 2 7 95 95 — 20 31 938 1,250 — 0 3 25 25
California 17 33 67 1,619 1,668 201 518 695 25,608 25,316 1 1 5 44 26
Hawaii 1 0 4 34 54 — 13 24 628 727 1 0 3 26 20
Oregon 4 7 20 347 477 23 27 60 1,386 1,026 — 1 6 71 64
Washington 6 7 57 355 455 48 50 79 2,468 2,787 — 0 1 3 9
Territories
American Samoa — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I. — — — — — — — — — — — — — — —
Guam — 0 0 — 3 — 0 5 6 99 — 0 0 — —
Puerto Rico — 0 4 38 92 — 6 14 312 301 — 0 0 — 1
U.S. Virgin Islands — 0 0 — — — 2 10 113 132 — 0 0 — —
C.N.M.I.: Commonwealth o f Northern Mariana Islands.
U: Unavailable. — : No reported cases. N: Not reportable. NN: Not Nationally Notifiable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.
* Case counts for reporting year 2011 are provisional and subject to  change. For further information on interpretation o f these data, see http://www.cdc.gov/osels/ph_surveillance/nndss/ 
phs/files/ProvisionalNationa%20NotifiableDiseasesSurveillanceData20100927.pdf. Data for TB are displayed in Table IV, which appears quarterly.
* Data for H. influenzae (age <5 yrs for serotype b, nonserotype b, and unknown serotype) are available in Table I.
§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
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TABLE II. (Continued) Provisional cases o f selected notifiable diseases, United States, weeks ending December 17, 2011, and December 18, 2010 (50th week)*

































United States 6 22 74 1,096 1,574 3C 47 167 2,399 3,155 12 18 39 96C 799
New England — 1 5 67 93 — 1 8 76 54 — 1 5 6C 54
Connecticut — 0 3 19 28 — 0 4 16 22 — 0 5 4C 37
Maine* — 0 2 6 7 — 0 2 8 13 — 0 2 4 2
Massachusetts — 0 3 31 48 — 1 6 49 12 — 0 2 11 13
New Hampshire — 0 1 — 1 — 0 1 3 5 N 0 C N N
Rhode Island* — 0 1 5 9 U 0 C U U U 0 C U U
Vermont* — 0 2 6 — — 0 C — 2 — 0 1 5 2
Mid. A tlantic 1 3 7 163 269 3 5 11 2C7 272 3 1 5 84 1C1
New Jersey — 0 2 — 73 — 0 2 — 74 — 0 C — 28
New York (Upstate) 1 1 4 46 56 2 1 9 54 5C 1 1 4 48 44
New York City — 1 5 62 88 — 1 5 78 79 — 0 C — 3
Pennsylvania — 1 3 55 52 1 2 4 75 69 2 0 4 36 26
E.N. Central 1 3 8 174 2C2 1 6 37 316 466 2 2 8 134 92
Illinois — 1 4 53 48 — 1 6 59 128 — 0 2 7 1
Indiana — 0 3 12 12 — 1 3 57 71 — 0 5 55 27
Michigan 1 1 6 64 73 1 1 6 8C 119 2 1 4 64 45
Ohio — 1 3 39 47 — 1 3C 89 94 — 0 1 6 9
Wisconsin — 0 1 6 22 — 0 3 31 54 — 0 1 2 1C
W.N. Central — 1 25 39 75 — 2 16 123 114 — 0 6 8 2C
Iowa — 0 1 8 11 — 0 1 1C 14 — 0 C — —
Kansas — 0 2 3 11 — 0 2 12 11 — 0 1 3 2
Minnesota — 0 22 9 15 — 0 15 9 8 — 0 6 2 1C
Missouri — 0 1 12 2C — 2 5 79 67 — 0 C — 6
Nebraska* — 0 1 5 14 — 0 3 12 12 — 0 1 3 2
North Dakota — 0 1 — 3 — 0 C — — — 0 C — —
South Dakota — 0 2 2 1 — 0 1 1 2 — 0 C — —
S. A tlantic 1 4 12 227 332 12 12 56 668 872 6 4 11 231 182
Delaware — 0 1 2 7 — 0 2 13 24 U 0 C U U
District o f Columbia — 0 C — 1 — 0 C — 3 — 0 C — 2
Florida 1 1 7 79 137 7 4 7 199 29C 1 1 3 56 55
Georgia — 1 5 48 37 — 2 7 113 163 — 0 3 33 32
Maryland* — 0 4 25 22 2 1 4 58 66 1 0 3 35 24
North Carolina — 0 3 27 45 2 2 12 106 108 4 1 7 6C 39
South Carolina* — 0 2 1C 26 — 1 3 32 58 — 0 1 1 1
Virginia* — 0 3 28 49 1 1 6 68 9C — 0 3 2C 12
West Virginia — 0 5 8 8 — 0 43 79 7C — 0 6 26 17
E.S. Central — 1 6 47 48 7 10 15 459 37C 1 4 1C 215 157
Alabama* — 0 2 7 8 1 2 6 109 65 — 0 3 18 7
Kentucky — 0 2 1C 26 2 3 7 136 132 — 2 7 121 106
Mississippi — 0 1 7 2 — 1 4 44 33 U 0 C U U
Tennessee* — 0 5 23 12 4 4 8 17C 14C 1 1 5 76 44
W.S. Central 1 3 15 128 141 3 6 67 296 553 — 2 11 83 68
Arkansas* — 0 1 1 2 — 1 4 48 62 — 0 C — 1
Louisiana — 0 2 5 11 — 1 4 34 51 — 0 2 5 4
Oklahoma — 0 4 3 2 1 1 16 82 97 — 1 1C 47 31
Texas* 1 2 11 119 126 2 3 45 132 343 — 0 3 31 32
M ountain — 1 5 57 14C 1 1 4 73 133 — 1 5 62 64
Arizona — 0 2 16 61 — 0 3 16 26 U 0 C U U
Colorado — 0 2 18 35 — 0 2 15 44 — 0 3 17 19
Idaho* — 0 1 6 7 — 0 1 2 6 — 0 2 1C 11
Montana* — 0 1 2 4 — 0 C — — — 0 1 3 3
Nevada* — 0 3 5 14 1 0 3 27 41 — 0 2 1C 7
New Mexico* — 0 1 5 5 — 0 2 8 5 — 0 2 12 14
Utah — 0 2 3 1C — 0 1 5 8 — 0 2 8 1C
W yoming* — 0 1 2 4 — 0 C — 3 — 0 1 2 —
Pacific 2 3 13 194 274 3 3 25 181 321 — 2 12 83 61
Alaska — 0 1 2 5 — 0 1 4 5 U 0 C U U
California 1 3 12 151 225 — 2 22 114 227 — 1 4 38 27
Hawaii — 0 2 8 7 — 0 1 6 6 U 0 C U U
Oregon — 0 2 9 17 2 0 4 31 4C — 0 3 13 15
Washington 1 0 4 24 2C 1 0 4 26 43 — 0 5 32 19
Territories
American Samoa — C C — — — C C — — — C C — —
C.N.M.I. — — — — — — — — — — — — — — —
Guam — C 5 8 7 — 2 8 28 77 — C 3 1C 61
Puerto Rico — C 1 7 2C — C 2 8 28 N C C N N
U.S. Virgin Islands — C C — — — C C — — — C C — —
C.N.M.I.: Commonwealth o f Northern Mariana Islands.
U: Unavailable. — : No reported cases. N: Not reportable. NN: Not Nationally Notifiable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.
* Case counts for reporting year 2011 are provisional and subject to  change. For further information on interpretation o f these data, see http://www.cdc.gov/osels/ph_surveillance/nndss/ 
phs/files/ProvisionalNationa%20NotifiableDiseasesSurveillanceData20100927.pdf. Data for TB are displayed in Table IV, which appears quarterly.
* Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
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TABLE II. (Continued) Provisional cases o f selected notifiable diseases, United States, weeks ending December 17, 2011, and December 18, 2010 (50th week)*






























United States 29 56 160 3,550 3,225 175 323 1,470 23,045 29,538 7 25 114 1,309 1,641
New England _ 5 39 390 264 1 76 493 6,743 8,838 _ 2 20 87 102
Connecticut — 1 10 74 53 _ 30 227 2,606 3,033 _ 0 20 12 2
Maine* _ 0 3 18 11 _ 13 66 911 709 _ 0 2 6 6
Massachusetts _ 3 24 235 127 _ 19 106 1,354 3,255 _ 1 6 56 71
New Hampshire — 0 3 24 22 _ 15 86 1,131 1,313 _ 0 1 2 5
Rhode Island* _ 0 9 28 42 _ 1 31 147 181 _ 0 2 5 15
Vermont* _ 0 2 11 9 1 6 67 594 347 _ 0 1 6 3
Mid. Atlantic 9 14 72 1,052 916 150 143 741 11,048 10,677 _ 6 13 303 503
New Jersey _ 0 2 _ 148 _ 0 34 _ 3,657 _ 0 2 _ 102
New York (Upstate) 7 5 27 371 286 56 50 213 3,664 2,540 _ 1 4 50 75
New York City _ 3 14 200 161 _ 1 12 110 720 _ 4 10 198 268
Pennsylvania 2 5 37 481 321 94 90 516 7,274 3,760 _ 1 5 55 58
E.N. Central 5 11 51 791 669 1 15 163 1,521 3,811 _ 3 10 151 161
Illinois _ 1 11 121 145 _ 1 18 164 135 _ 1 5 55 60
Indiana _ 2 7 109 55 _ 1 15 100 78 _ 0 2 9 15
Michigan 1 3 15 188 178 1 1 12 107 94 _ 0 4 32 31
Ohio 4 6 34 372 229 _ 1 6 51 41 _ 1 4 41 41
Wisconsin _ 0 1 1 62 _ 12 121 1,099 3,463 _ 0 2 14 14
W.N. Central _ 1 8 79 122 _ 1 15 136 2,085 _ 1 45 56 70
Iowa _ 0 2 11 15 _ 0 12 82 85 _ 0 3 22 14
Kansas _ 0 2 11 12 _ 0 2 13 10 _ 0 2 9 13
Minnesota _ 0 4 _ 35 _ 0 3 _ 1,954 _ 0 45 _ 3
Missouri _ 1 5 47 37 _ 0 2 8 4 _ 0 2 20 21
Nebraska* _ 0 1 6 9 _ 0 2 8 8 _ 0 1 4 15
North Dakota _ 0 1 2 5 _ 0 10 21 23 _ 0 0 _ 1
South Dakota _ 0 1 2 9 _ 0 2 4 1 _ 0 1 1 3
S. A tlantic 6 10 29 569 540 18 54 172 3,337 3,766 3 8 24 425 438
Delaware _ 0 4 24 17 _ 12 48 804 644 _ 0 3 7 2
District o f Columbia _ 0 3 9 18 _ 0 3 31 41 _ 0 1 5 13
Florida 3 3 13 180 164 5 2 7 126 80 2 2 6 100 131
Georgia _ 1 3 41 63 _ 0 5 25 10 _ 1 5 73 69
Maryland* 1 2 14 128 110 9 19 114 1,231 1,611 1 2 14 125 99
North Carolina 1 1 7 77 62 _ 0 12 70 80 _ 0 6 38 52
South Carolina* _ 0 5 22 16 _ 0 6 33 29 _ 0 1 6 6
Virginia* 1 1 7 82 76 4 16 76 940 1,151 _ 1 8 71 63
West Virginia _ 0 2 6 14 _ 0 14 77 120 _ 0 0 _ 3
E.S. Central 2 2 11 163 132 1 1 5 61 43 _ 0 4 35 31
Alabama* _ 0 2 26 22 1 0 2 22 2 _ 0 3 6 9
Kentucky _ 1 4 47 27 _ 0 1 2 5 _ 0 2 9 8
Mississippi _ 0 3 13 12 _ 0 1 3 _ _ 0 1 1 2
Tennessee* 2 1 8 77 71 _ 0 4 34 36 _ 0 3 19 12
W.S. Central 1 2 13 130 168 2 1 29 52 112 1 0 18 31 95
Arkansas* _ 0 2 14 19 _ 0 0 _ _ _ 0 1 5 4
Louisiana _ 0 3 18 11 _ 0 1 1 3 _ 0 1 1 5
Oklahoma _ 0 3 9 13 _ 0 0 _ _ 1 0 1 6 5
Texas* 1 2 11 89 125 2 1 29 51 109 _ 0 17 19 81
M ountain _ 2 8 103 168 _ 0 4 42 28 1 1 5 62 65
Arizona _ 1 4 42 64 _ 0 2 11 2 _ 0 4 22 28
Colorado _ 0 1 6 31 _ 0 1 1 3 1 0 3 22 21
Idaho* _ 0 1 8 8 _ 0 2 4 9 _ 0 1 2 3
Montana* _ 0 1 1 4 _ 0 3 11 4 _ 0 1 2 3
Nevada* _ 0 2 16 20 _ 0 1 4 2 _ 0 2 8 6
New Mexico* _ 0 2 11 9 _ 0 2 5 5 _ 0 1 3 1
Utah _ 0 2 15 24 _ 0 1 4 3 _ 0 1 3 3
W yoming* _ 0 2 4 8 _ 0 1 2 _ _ 0 0 _ _
Pacific 6 5 21 273 246 2 2 11 105 178 2 3 11 159 176
Alaska _ 0 0 _ 2 _ 0 2 12 7 _ 0 2 5 5
California 5 4 15 229 202 _ 1 9 64 118 2 2 8 108 115
Hawaii _ 0 2 3 2 N 0 0 N N _ 0 1 8 4
Oregon _ 0 3 19 16 _ 0 2 12 39 _ 0 4 17 14
Washington 1 0 6 22 24 2 0 6 17 14 _ 0 3 21 38
Territories
American Samoa N 0 0 N N N 0 0 N N _ 0 1 1 _
C.N.M.I. _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
Guam _ 0 0 _ 1 _ 0 0 _ _ _ 0 0 _ _
Puerto Rico _ 0 0 _ 2 N 0 0 N N _ 0 0 _ 5
U.S. Virgin Islands _ 0 0 _ _ _ 0 0 _ _ _ 0 0 _ _
C.N.M.I.: Commonwealth o f Northern Mariana Islands.
U: Unavailable. — : No reported cases. N: Not reportable. NN: Not Nationally Notifiable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.
* Case counts for reporting year 2011 are provisional and subject to  change. For further information on interpretation o f these data, see http://www.cdc.gov/osels/ph_surveillance/nndss/ 
phs/files/ProvisionalNationa%20NotifiableDiseasesSurveillanceData20100927.pdf. Data for TB are displayed in Table IV, which appears quarterly.
+ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
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TABLE II. (Continued) Provisional cases o f selected notifiable diseases, United States, weeks ending December 17, 2011, and December 18, 2010 (50th week)*
Meningococcal disease, invasive* 




























United States 2 12 53 643 761 4 7 47 337 2,547 168 287 2,925 14,249 23,983
New England _ 0 3 29 21 _ 0 2 10 25 3 14 32 700 507
Connecticut _ 0 1 3 3 _ 0 0 _ 11 _ 1 5 56 105
Maine5 _ 0 1 5 5 _ 0 2 2 2 2 3 19 199 51
Massachusetts _ 0 2 14 7 _ 0 1 4 9 _ 4 10 222 274
New Hampshire _ 0 1 1 _ _ 0 0 _ 3 1 2 13 143 20
Rhode Island5 _ 0 1 1 1 _ 0 2 3 _ _ 0 4 28 40
Vermont5 _ 0 3 5 5 _ 0 1 1 _ _ 0 10 52 17
Mid. Atlantic _ 1 5 70 77 _ 1 23 48 2,115 54 31 112 1,731 1,801
New Jersey _ 0 1 _ 21 _ 0 2 10 353 _ 3 10 168 164
New York (Upstate) _ 0 4 22 12 _ 0 3 11 663 42 12 81 756 610
New York City _ 0 3 28 18 _ 0 22 24 1,039 _ 2 41 150 85
Pennsylvania _ 0 2 20 26 _ 0 8 3 60 12 12 40 657 942
E.N. Central _ 2 6 94 127 1 2 6 85 79 28 65 129 3,120 5,512
Illinois _ 0 3 28 23 _ 1 5 54 29 _ 17 49 883 1,001
Indiana _ 0 2 19 29 _ 0 1 1 4 _ 4 18 243 729
Michigan _ 0 2 11 22 _ 0 2 11 18 6 12 41 632 1,497
Ohio _ 0 2 23 32 1 0 2 15 23 19 13 45 733 1,738
Wisconsin _ 0 2 13 21 _ 0 1 4 5 3 12 26 629 547
W.N. Central _ 1 3 51 57 _ 0 4 32 81 10 20 501 1,117 2,384
Iowa _ 0 1 14 10 _ 0 1 5 38 _ 4 15 194 670
Kansas _ 0 1 4 8 _ 0 1 4 4 _ 2 8 87 177
Minnesota _ 0 1 _ 8 _ 0 4 1 4 _ 0 469 326 662
Missouri _ 0 3 18 23 _ 0 3 12 10 10 6 26 378 589
Nebraska5 _ 0 2 11 6 _ 0 1 6 23 _ 1 7 51 206
North Dakota _ 0 1 1 2 _ 0 3 4 _ _ 0 10 51 51
South Dakota _ 0 1 3 _ _ 0 0 _ 2 _ 0 7 30 29
S. A tlantic _ 2 8 125 129 _ 0 4 36 56 15 26 106 1,340 1,854
Delaware _ 0 1 1 1 _ 0 0 _ _ 1 0 5 23 14
District o f Columbia _ 0 1 1 1 _ 0 0 _ 3 _ 0 2 6 15
Florida _ 1 5 49 58 _ 0 2 10 8 4 6 17 309 307
Georgia _ 0 1 14 12 _ 0 2 5 5 1 3 8 167 238
Maryland5 _ 0 1 13 9 _ 0 1 2 11 _ 2 8 114 135
North Carolina _ 0 3 15 13 _ 0 2 9 10 8 2 35 177 337
South Carolina5 _ 0 1 9 12 _ 0 1 1 4 1 2 25 140 363
Virginia5 _ 0 2 16 21 _ 0 4 9 13 _ 6 41 341 320
West Virginia _ 0 3 7 2 _ 0 0 _ 2 _ 0 41 63 125
E.S. Central 1 0 3 26 43 _ 0 1 5 10 8 9 25 439 822
Alabama5 _ 0 2 10 8 _ 0 1 1 6 _ 2 11 129 200
Kentucky _ 0 2 5 17 _ 0 0 _ 1 3 3 16 164 291
Mississippi _ 0 1 3 5 _ 0 1 3 _ 1 0 3 41 105
Tennessee5 1 0 2 8 13 _ 0 1 1 3 4 2 10 105 226
W.S. Central _ 1 12 57 86 3 1 15 67 117 9 20 297 895 2,982
Arkansas5 _ 0 2 12 6 _ 0 2 3 5 _ 1 16 58 226
Louisiana _ 0 2 12 15 _ 0 0 _ 8 _ 0 3 17 46
Oklahoma _ 0 2 10 16 _ 0 2 4 _ _ 0 92 52 91
Texas5 _ 0 10 23 49 3 1 14 60 104 9 18 187 768 2,619
M ountain 1 1 4 47 55 _ 0 2 8 20 28 37 79 1,932 1,826
Arizona _ 0 1 11 13 _ 0 0 _ 5 _ 13 28 656 516
Colorado 1 0 1 10 21 _ 0 1 3 7 22 8 31 424 487
Idaho5 _ 0 1 7 5 _ 0 2 2 1 6 2 12 179 185
Montana5 _ 0 2 4 2 _ 0 0 _ _ _ 1 32 130 113
Nevada5 _ 0 1 5 8 _ 0 0 _ 1 _ 0 5 31 38
New Mexico5 _ 0 1 2 3 _ 0 1 2 2 _ 3 23 249 143
Utah _ 0 2 8 1 _ 0 0 _ 3 _ 5 16 254 332
W yoming5 _ 0 1 _ 2 _ 0 1 1 1 _ 0 1 9 12
Pacific _ 3 26 144 166 _ 0 11 46 44 13 61 1,710 2,975 6,295
Alaska _ 0 1 3 1 _ 0 1 1 1 _ 0 4 25 41
California _ 2 17 100 110 _ 0 11 37 29 4 37 1,569 1,940 5,462
Hawaii _ 0 1 4 1 _ 0 1 2 4 2 1 9 92 64
Oregon _ 0 3 22 31 _ 0 1 4 3 3 5 23 295 276
Washington _ 0 8 15 23 _ 0 1 2 7 4 11 131 623 452
Territories
American Samoa _ 0 0 _ _ _ 0 0 _ _ _ 0 0 _ _
C.N.M.I. _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
Guam _ 0 0 _ _ _ 1 3 12 484 _ 2 14 31 3
Puerto Rico _ 0 0 _ 2 _ 0 1 1 1 _ 0 1 2 4
U.S. Virgin Islands _ 0 0 _ _ _ 0 0 _ _ _ 0 0 _ _
C.N.M.I.: Commonwealth o f Northern Mariana Islands.
U: Unavailable. — : No reported cases. N: Not reportable. NN: Not Nationally Notifiable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.
* Case counts for reporting year 2011 are provisional and subject to  change. For further information on interpretation o f these data, see http://www.cdc.gov/osels/ph_surveillance/nndss/ 
phs/files/ProvisionalNationa%20NotifiableDiseasesSurveillanceData20100927.pdf. Data for TB are displayed in Table IV, which appears quarterly.
* Data for meningococcal disease, invasive caused by serogroups A, C, Y, and W-135; serogroup B; other serogroup; and unknown serogroup are available in Table I.
§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
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TABLE II. (Continued) Provisional cases o f selected notifiable diseases, United States, weeks ending December 17, 2011, and December 18, 2010 (50th week)*
































United States 19 57 119 2,863 4,172 396 856 1,816 44,66C 52,475 41 89 264 4,832 5,154
New England 2 4 16 253 3C1 5 36 1C7 2,C28 2,3C6 — 3 13 2C9 2C9
Connecticut — 2 1C 121 142 — 8 3C 445 491 — 1 4 53 6C
Maine5 — 1 6 63 62 — 2 8 127 128 — 0 3 29 21
Massachusetts — 0 C — — — 19 44 1,041 1,266 — 1 9 8C 82
New Hampshire 2 0 3 2C 17 1 3 8 159 171 — 0 3 24 21
Rhode Island5 — 0 6 25 29 4 1 62 181 17C — 0 2 7 3
Vermont5 — 0 2 24 51 — 1 8 75 8C — 0 3 16 22
Mid. A tlantic 5 15 35 81C 1,C28 32 72 169 4,218 5,7C5 5 8 3C 484 559
New Jersey — 0 C — — — 0 15 — 1,176 — 0 2 — 125
New York (Upstate) 5 7 2C 361 485 18 25 67 1,356 1,388 5 3 12 213 196
New York City — 0 3 9 145 — 19 42 1,C85 1,288 — 1 6 89 79
Pennsylvania — 8 21 44C 398 14 30 111 1,777 1,853 — 3 18 182 159
E.N. Central — 2 17 18C 228 22 83 157 4,2C8 5,736 2 14 49 842 797
Illinois — 0 6 5C 114 — 27 8C 1,527 1,942 — 4 14 215 152
Indiana — 0 7 26 — — 7 19 351 755 — 1 8 86 139
Michigan — 1 6 57 68 8 14 42 814 918 — 3 19 179 152
Ohio — 1 5 47 46 14 21 46 1,162 1,286 2 3 1C 18C 135
Wisconsin N 0 C N N — 7 45 354 835 — 2 2C 182 219
W.N. Central 1 1 4C 78 241 14 40 103 2,245 2,942 5 11 4C 725 895
Iowa — 0 C — 27 1 9 19 441 52C — 2 15 183 17C
Kansas — 0 4 31 59 — 8 28 443 426 — 1 8 104 76
Minnesota — 0 34 — 25 — 0 6 — 7CC — 0 2 — 287
Missouri 1 0 C 1 63 13 16 46 933 821 5 5 32 292 233
Nebraska5 — 0 3 33 51 — 4 13 232 243 — 1 7 95 77
North Dakota — 0 6 13 16 — 0 15 41 51 — 0 4 13 17
South Dakota — 0 C — — — 3 1C 155 181 — 1 4 38 35
S. A tlantic 6 15 93 1,C23 1,113 167 267 722 14,191 15,450 8 12 28 645 721
Delaware — 0 C — — — 2 11 164 175 — 0 2 15 6
District o f Columbia — 0 C — — — 1 5 52 91 — 0 1 3 9
Florida — 0 84 117 121 1C5 107 2C3 5,732 6,124 5 3 15 15C 217
Georgia — 0 C — — 15 40 127 2,361 2,75C — 2 8 116 98
Maryland5 — 5 13 247 358 14 18 42 931 1,C64 3 1 6 59 106
North Carolina — 0 C — — 21 31 251 2,27C 2,271 — 2 11 12C 97
South Carolina5 N 0 C N N 6 26 7C 1,481 1,675 — 0 4 15 24
Virginia5 6 11 27 578 557 6 21 68 1,155 1,123 — 3 9 164 139
West Virginia — 0 3C 81 77 — 0 14 45 177 — 0 2 3 25
E.S. Central 1 3 11 17C 169 18 61 19C 4,C75 3,898 1 5 18 263 267
Alabama5 1 2 7 81 69 7 18 7C 1,199 1,C38 — 0 15 71 55
Kentucky — 0 2 16 21 — 10 3C 569 583 — 1 5 67 7C
Mississippi — 0 1 1 — 3 21 66 1,315 1,2C3 — 0 4 24 3C
Tennessee5 — 1 6 72 79 8 16 52 992 1,074 1 1 11 1C1 112
W.S. Central 3 1 31 112 826 56 118 515 6,371 7,217 2 9 151 418 367
Arkansas5 3 0 1C 57 34 1C 14 53 842 763 — 1 6 6C 48
Louisiana — 0 C — — 5 14 44 971 1,342 — 0 1 12 2C
Oklahoma — 0 21 55 42 14 12 95 713 651 1 1 55 71 49
Texas5 — 0 12 — 75C 27 83 381 3,845 4,461 1 6 95 275 25C
M ountain 1 0 4 42 66 25 44 93 2,381 2,834 3 10 26 532 668
Arizona N 0 C N N 13 14 34 775 978 1 2 7 81 98
Colorado — 0 C — — 9 10 24 528 561 1 2 7 106 219
Idaho5 — 0 1 6 11 — 3 8 141 162 — 2 8 116 108
Montana5 N 0 C N N 2 2 1C 124 94 1 0 5 39 41
Nevada5 — 0 2 16 8 1 3 8 158 3C2 — 0 7 39 41
New Mexico5 1 0 2 13 13 — 5 22 3C9 333 — 1 3 41 49
Utah — 0 2 7 1C — 5 15 291 342 — 1 7 85 93
W yoming5 — 0 C — 24 — 1 9 55 62 — 0 7 25 19
Pacific — 3 15 195 2CC 57 100 288 4,943 6,387 15 15 46 714 671
Alaska — 0 2 12 12 — 1 6 52 79 — 0 1 4 2
California — 3 12 169 171 32 74 232 3,777 4,767 6 9 36 442 31C
Hawaii — 0 C — — 3 7 14 332 318 — 0 2 9 28
Oregon — 0 1 14 17 1 5 12 251 5C1 1 1 11 1C1 115
Washington — 0 14 — — 21 9 42 531 722 8 2 13 158 216
Territories
American Samoa N C C N N — C C — 2 — C C — —
C.N.M.I. — — — — — — — — — — — — — — —
Guam — C C — — — C 3 6 11 — C C — —
Puerto Rico — C 6 38 41 3 3 12 193 6C4 — C C — —
U.S. Virgin Islands — C C — — — C C — — — C C — —
C.N.M.I.: Commonwealth o f Northern Mariana Islands.
U: Unavailable. — : No reported cases. N: Not reportable. NN: Not Nationally Notifiable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.
* Case counts for reporting year 2011 are provisional and subject to  change. For further information on interpretation o f these data, see http://www.cdc.gov/osels/ph_surveillance/nndss/ 
phs/files/ProvisionalNationa%20NotifiableDiseasesSurveillanceData20100927.pdf. Data for TB are displayed in Table IV, which appears quarterly.
+ Includes E. coli O157:H7; Shiga toxin-positive, serogroup non-O157; and Shiga toxin-positive, not serogrouped.
§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
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TABLE II. (Continued) Provisional cases o f selected notifiable diseases, United States, weeks ending December 17, 2011, and December 18, 2010 (50th week)*



























United States 165 233 742 11,244 13,765 3 3 15 202 145 9 26 245 1,952 1,570
New England _ 5 21 261 316 _ 0 1 1 _ _ 0 1 8 5
Connecticut — 0 4 37 69 _ 0 0 _ _ _ 0 0 _ _
Maine5 _ 0 8 32 8 _ 0 0 _ _ _ 0 1 1 2
Massachusetts _ 3 20 175 208 _ 0 0 _ _ _ 0 1 4 _
New Hampshire — 0 1 3 14 _ 0 1 1 _ _ 0 1 1 1
Rhode Island5 _ 0 3 8 16 _ 0 0 _ _ _ 0 1 2 2
Vermont5 _ 0 1 6 1 _ 0 0 _ _ _ 0 0 _ _
Mid. A tlantic 20 14 74 809 1,558 1 0 2 20 2 3 1 4 59 101
New Jersey _ 0 3 _ 367 _ 0 0 _ 1 _ 0 1 _ 59
New York (Upstate) 18 5 20 322 218 1 0 1 5 1 2 0 1 10 17
New York City 2 6 27 369 294 _ 0 0 _ _ _ 0 3 29 11
Pennsylvania _ 2 56 118 679 _ 0 2 15 _ 1 0 3 20 14
E.N. Central 7 14 40 716 1,516 1 0 2 9 3 _ 2 9 113 77
Illinois _ 4 16 204 828 _ 0 1 2 2 _ 1 4 47 34
Indiana5 _ 1 4 45 62 _ 0 1 2 1 _ 0 4 46 20
Michigan 1 3 10 169 251 1 0 1 2 _ _ 0 1 2 1
Ohio 6 4 27 298 302 _ 0 2 3 _ _ 0 2 18 15
Wisconsin _ 0 1 _ 73 _ 0 0 _ _ _ 0 0 _ 7
W.N. Central 1 5 18 288 2,042 _ 0 4 27 13 1 4 29 346 275
Iowa _ 0 4 20 55 _ 0 0 _ _ _ 0 2 7 5
Kansas5 _ 1 6 60 291 _ 0 0 _ _ _ 0 0 _ _
Minnesota _ 0 2 _ 66 _ 0 0 _ _ _ 0 2 _ _
Missouri 1 3 14 188 1,567 _ 0 3 19 10 1 4 29 334 267
Nebraska5 _ 0 2 14 56 _ 0 3 5 3 _ 0 1 5 2
North Dakota _ 0 0 _ _ _ 0 1 2 _ _ 0 0 _ 1
South Dakota _ 0 2 6 7 _ 0 1 1 _ _ 0 0 _ _
S. A tlantic 65 73 134 3,691 2,657 1 1 8 104 82 3 6 55 550 503
Delaware5 _ 0 2 6 39 _ 0 1 1 1 _ 0 4 18 21
District o f Columbia _ 0 5 20 34 _ 0 1 1 1 _ 0 1 3 _
Florida5 49 50 98 2,575 1,135 _ 0 1 3 3 1 0 2 13 11
Georgia 10 10 24 567 777 _ 1 6 65 57 _ 0 0 _ _
Maryland5 2 1 7 98 129 1 0 1 4 _ _ 0 2 30 49
North Carolina 1 3 19 205 237 _ 0 4 15 15 _ 0 49 264 269
South Carolina5 1 1 52 117 69 _ 0 2 11 1 _ 0 2 21 19
Virginia5 2 2 8 99 133 _ 0 1 4 4 2 3 14 197 134
West Virginia _ 0 5 4 104 _ 0 0 _ _ _ 0 1 4 _
E.S. Central 3 17 46 930 770 _ 0 2 14 20 2 4 25 334 403
Alabama5 1 5 21 285 229 _ 0 1 5 5 1 1 8 73 78
Kentucky _ 3 22 227 221 _ 0 1 3 6 _ 0 1 1 _
Mississippi 1 4 24 228 58 _ 0 0 _ 1 _ 0 2 12 25
Tennessee5 1 4 11 190 262 _ 0 2 6 8 1 3 20 248 300
W.S. Central 41 52 503 2,711 2,852 _ 0 8 11 7 _ 2 235 485 185
Arkansas5 2 2 7 78 77 _ 0 3 6 2 _ 0 50 416 130
Louisiana 3 5 21 277 287 _ 0 0 _ _ _ 0 2 7 3
Oklahoma 8 2 161 207 254 _ 0 5 3 3 _ 0 202 43 26
Texas5 28 42 338 2,149 2,234 _ 0 1 2 2 _ 0 5 19 26
M ountain 10 15 42 794 836 _ 0 4 15 12 _ 1 7 57 20
Arizona 6 5 27 369 459 _ 0 4 15 9 _ 0 6 40 8
Colorado5 1 1 8 99 96 _ 0 0 _ 1 _ 0 1 2 1
Idaho5 _ 0 3 16 23 _ 0 0 _ _ _ 0 1 1 5
Montana5 1 1 15 123 9 _ 0 0 _ 2 _ 0 1 1 1
Nevada5 2 0 4 33 48 _ 0 0 _ _ _ 0 1 2 _
New Mexico5 _ 2 7 105 154 _ 0 0 _ _ _ 0 0 _ 1
Utah _ 1 4 47 47 _ 0 0 _ _ _ 0 1 1 3
W yoming5 _ 0 1 2 _ _ 0 0 _ _ _ 0 2 10 1
Pacific 18 20 63 1,044 1,218 _ 0 2 1 6 _ 0 0 _ 1
Alaska _ 0 2 5 2 N 0 0 N N N 0 0 N N
California 6 16 59 859 1,002 _ 0 1 1 6 _ 0 0 _ _
Hawaii _ 1 3 44 46 N 0 0 N N N 0 0 N N
Oregon 2 1 4 44 58 _ 0 0 _ _ _ 0 0 _ 1
Washington 10 1 6 92 110 _ 0 1 _ _ _ 0 0 _ _
Territories
American Samoa _ 0 1 1 4 N 0 0 N N N 0 0 N N
C.N.M.I. _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
Guam _ 0 1 1 5 N 0 0 N N N 0 0 N N
Puerto Rico _ 0 1 _ 6 N 0 0 N N N 0 0 N N
U.S. Virgin Islands _ 0 0 _ _ _ 0 0 _ _ _ 0 0 _ _
C.N.M.I.: Commonwealth o f Northern Mariana Islands.
U: Unavailable. — : No reported cases. N: Not reportable. NN: Not Nationally Notifiable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.
* Case counts for reporting year 2011 are provisional and subject to  change. For further information on interpretation o f these data, see http://www.cdc.gov/osels/ph_surveillance/nndss/ 
phs/files/ProvisionalNationa%20NotifiableDiseasesSurveillanceData20100927.pdf. Data for TB are displayed in Table IV, which appears quarterly.
* Illnesses w ith similar clinical presentation that result from Spotted fever group rickettsia infections are reported as Spotted fever rickettsioses. Rocky Mountain spotted fever (RMSF) caused 
by Rickettsia rickettsii, is the most common and well-known spotted fever.
§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
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TABLE II. (Continued) Provisional cases o f selected notifiable diseases, United States, weeks ending December 17, 2011, and December 18, 2010 (50th week)*
Streptococcus pneumoniae,+ invasive disease




























United States 154 241 937 12,202 15,052 17 24 118 1,149 2,019 69 262 363 12,325 13,213
New England 3 13 79 678 851 _ 1 5 45 100 1 7 16 356 463
Connecticut _ 6 49 282 340 _ 0 3 10 27 _ 0 5 41 93
Maine5 2 2 13 124 116 _ 0 1 4 10 _ 0 2 12 31
Massachusetts _ 1 3 35 67 _ 0 2 18 44 _ 5 10 237 277
New Hampshire _ 2 8 97 129 _ 0 1 5 5 _ 0 3 18 22
Rhode Island5 _ 1 6 73 117 _ 0 1 2 8 _ 0 7 39 37
Vermont5 1 1 6 67 82 _ 0 2 6 6 1 0 2 9 3
Mid. A tlantic 8 14 81 691 1,576 2 1 27 75 232 11 31 53 1,474 1,636
New Jersey _ 0 29 _ 705 _ 0 4 _ 58 _ 5 13 212 235
New York (Upstate) 3 1 10 83 144 2 1 9 46 110 5 3 20 181 124
New York City 5 11 42 608 727 _ 0 14 29 64 2 15 30 725 921
Pennsylvania N 0 0 N N N 0 0 N N 4 6 15 356 356
E.N. Central 45 61 115 2,897 3,123 5 5 13 240 358 _ 30 47 1,429 1,839
Illinois N 0 0 N N _ 1 6 73 95 _ 12 24 584 880
Indiana 1 13 33 648 733 _ 1 3 32 55 _ 3 8 153 169
Michigan 3 14 26 631 710 _ 1 3 34 80 _ 5 12 243 227
Ohio 35 26 44 1,207 1,175 3 2 7 80 94 _ 8 17 398 514
Wisconsin 6 8 24 411 505 2 0 3 21 34 _ 1 5 51 49
W.N. Central _ 2 33 162 829 _ 1 4 64 153 1 6 13 278 346
Iowa N 0 0 N N N 0 0 N N _ 0 3 18 18
Kansas N 0 0 N N N 0 0 N N _ 0 4 24 19
Minnesota _ 0 17 _ 620 _ 0 1 _ 85 _ 2 8 109 145
Missouri N 0 0 N N _ 0 4 36 39 _ 2 6 117 147
Nebraska5 _ 2 9 108 136 _ 0 2 12 16 1 0 2 9 10
North Dakota _ 0 25 54 73 _ 0 1 2 2 _ 0 1 1 3
South Dakota N 0 0 N N _ 0 2 14 11 _ 0 0 _ 4
S. A tlantic 44 66 170 3,524 4,000 5 6 25 325 540 34 68 178 3,268 3,072
Delaware _ 1 6 47 40 _ 0 1 _ _ 4 0 4 24 5
District o f Columbia _ 1 4 44 75 _ 0 1 5 9 2 3 8 152 132
Florida 26 22 68 1,265 1,401 3 3 13 127 188 5 24 36 1,151 1,157
Georgia 11 20 54 980 1,364 1 2 5 83 159 14 14 130 734 663
Maryland5 7 9 33 524 506 1 1 3 41 52 _ 8 20 417 308
North Carolina N 0 0 N N N 0 0 N N 4 8 19 366 383
South Carolina5 _ 7 25 408 493 _ 0 3 28 55 4 4 11 215 144
Virginia5 N 0 0 N N _ 0 3 27 55 1 4 12 207 274
West Virginia _ 0 48 256 121 _ 0 6 14 22 _ 0 1 2 6
E.S. Central 10 18 37 867 1,028 2 1 4 70 111 5 14 34 720 858
Alabama5 N 0 0 N N N 0 0 N N 1 4 11 201 249
Kentucky N 0 0 N N N 0 0 N N 4 2 16 120 122
Mississippi N 0 0 N N _ 0 2 11 17 _ 3 14 167 214
Tennessee5 10 18 37 867 1,028 2 1 4 59 94 _ 5 11 232 273
W.S. Central 25 31 368 1,709 1,843 3 4 38 197 287 6 35 50 1,711 2,030
Arkansas5 6 4 26 212 164 1 0 3 14 18 4 3 10 181 203
Louisiana _ 2 11 157 137 _ 0 2 16 27 2 6 25 366 537
Oklahoma N 0 0 N N 1 1 8 36 46 _ 1 4 50 88
Texas5 19 24 333 1,340 1,542 1 2 27 131 196 _ 23 37 1,114 1,202
M ountain 19 27 72 1,528 1,693 _ 3 8 118 221 _ 11 20 541 599
Arizona 11 12 45 714 772 _ 1 5 53 97 _ 5 10 226 218
Colorado 8 9 23 489 519 _ 0 4 33 63 _ 2 6 104 137
Idaho5 N 0 0 N N _ 0 1 5 8 _ 0 4 12 4
Montana5 N 0 0 N N N 0 0 N N _ 0 1 4 3
Nevada5 N 0 0 N N N 0 0 N N _ 2 9 127 124
New Mexico5 _ 4 13 225 157 _ 0 2 15 17 _ 1 4 57 51
Utah _ 1 8 77 216 _ 0 3 12 32 _ 0 2 11 62
W yoming5 _ 0 3 23 29 _ 0 0 _ 4 _ 0 0 _ _
Pacific _ 3 11 146 109 _ 0 2 15 17 11 53 74 2,548 2,370
Alaska _ 2 11 139 105 _ 0 1 11 17 _ 0 1 3 3
California N 0 0 N N N 0 0 N N 6 42 62 2,077 2,006
Hawaii _ 0 1 7 4 _ 0 1 4 _ _ 0 2 11 35
Oregon N 0 0 N N N 0 0 N N 2 4 14 185 70
Washington N 0 0 N N N 0 0 N N 3 5 11 272 256
Territories
American Samoa N 0 0 N N _ 0 0 _ _ _ 0 0 _ _
C.N.M.I. _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
Guam _ 0 0 _ _ _ 0 0 _ _ _ 0 0 _ _
Puerto Rico _ 0 0 _ _ _ 0 0 _ _ _ 4 14 232 215
U.S. Virgin Islands _ 0 0 _ _ _ 0 0 _ _ _ 0 0 _ _
C.N.M.I.: Commonwealth o f Northern Mariana Islands.
U: Unavailable. — : No reported cases. N: Not reportable. NN: Not Nationally Notifiable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.
* Case counts for reporting year 2011 are provisional and subject to  change. For further information on interpretation o f these data, see http://www.cdc.gov/osels/ph_surveillance/nndss/ 
phs/files/ProvisionalNationa%20NotifiableDiseasesSurveillanceData20100927.pdf. Data for TB are displayed in Table IV, which appears quarterly.
+ Includes drug resistant and susceptible cases o f invasive Streptococcus pneumoniae disease among children <5 years and among all ages. Case definition: Isolation o f S. pneumoniae from 
a normally sterile body site (e.g., blood or cerebrospinal fluid).
§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
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TABLE II. (Continued) Provisional cases o f selected notifiable diseases, United States, weeks ending December 17, 2011, and December 18, 2010 (50th week)*
West Nile virus disease*


























United States 147 256 364 11,542 14,856 — 0 59 460 629 — 0 32 222 392
New England 4 23 50 1,149 1,127 — 0 3 14 14 — 0 1 2 5
Connecticut 2 5 16 283 315 — 0 2 8 7 — 0 1 1 4
Maine1 — 4 11 201 237 — 0 0 — — — 0 0 — —
Massachusetts — 9 18 429 253 — 0 2 4 6 — 0 1 1 1
New Hampshire — 1 7 102 156 — 0 0 — 1 — 0 0 — —
Rhode Island1 — 0 6 34 46 — 0 1 1 — — 0 0 — —
Vermont1 2 1 9 100 120 — 0 1 1 — — 0 0 — —
Mid. Atlantic 15 19 42 963 1,685 — 0 11 34 123 — 0 6 22 63
New Jersey — 0 9 — 559 — 0 1 2 15 — 0 2 5 15
New York (Upstate) N 0 0 N N — 0 5 18 56 — 0 4 14 30
New York City — 0 0 — — — 0 4 9 33 — 0 1 2 9
Pennsylvania 15 19 39 963 1,126 — 0 2 5 19 — 0 1 1 9
E.N. Central 49 63 110 2,965 4,793 — 0 13 73 80 — 0 6 27 30
Illinois 1 14 31 713 1,183 — 0 6 22 45 — 0 5 12 16
Indiana1 11 5 20 268 355 — 0 2 7 6 — 0 1 2 7
Michigan 16 18 43 970 1,435 — 0 7 32 25 — 0 1 1 4
Ohio 21 21 58 1,012 1,311 — 0 3 10 4 — 0 3 11 1
Wisconsin — 0 13 2 509 — 0 1 2 — — 0 1 1 2
W.N. Central — 21 64 702 979 — 0 9 31 32 — 0 7 29 75
Iowa N 0 0 N N — 0 2 5 5 — 0 2 4 4
Kansas1 — 15 61 403 372 — 0 1 4 4 — 0 0 — 15
Minnesota — 0 1 1 — — 0 1 1 4 — 0 1 1 4
Missouri — 3 24 200 474 — 0 2 6 3 — 0 2 4 —
Nebraska1 — 0 2 7 25 — 0 4 14 10 — 0 3 15 29
North Dakota — 0 10 36 49 — 0 1 1 2 — 0 1 3 7
South Dakota — 1 6 55 59 — 0 0 — 4 — 0 1 2 16
S. A tlantic 10 32 65 1,674 2,049 — 0 10 52 38 — 0 7 28 22
Delaware1 — 0 1 8 39 — 0 1 1 — — 0 0 — —
District o f Columbia — 0 2 12 20 — 0 1 3 3 — 0 5 11 3
Florida1 7 17 38 837 952 — 0 5 20 9 — 0 2 3 3
Georgia N 0 0 N N — 0 2 7 4 — 0 1 5 9
Maryland1 N 0 0 N N — 0 5 10 17 — 0 3 9 6
North Carolina N 0 0 N N — 0 1 2 — — 0 0 — —
South Carolina1 — 0 9 12 77 — 0 0 — 1 — 0 0 — —
Virginia1 3 8 26 437 529 — 0 2 8 4 — 0 0 — 1
West Virginia — 5 32 368 432 — 0 1 1 — — 0 0 — —
E.S. Central 5 5 15 258 298 — 0 11 55 8 — 0 5 25 10
Alabama1 4 5 14 245 289 — 0 2 5 1 — 0 0 — 2
Kentucky N 0 0 N N — 0 2 4 2 — 0 1 1 1
Mississippi 1 0 3 13 9 — 0 5 30 3 — 0 4 22 5
Tennessee1 N 0 0 N N — 0 3 16 2 — 0 1 2 2
W.S. Central 49 48 258 2,609 2,769 — 0 4 26 104 — 0 3 11 20
Arkansas1 — 5 20 292 192 — 0 1 1 6 — 0 0 — 1
Louisiana — 1 6 75 89 — 0 1 6 20 — 0 2 4 7
Oklahoma N 0 0 N N — 0 0 — 1 — 0 0 — —
Texas1 49 43 247 2,242 2,488 — 0 3 19 77 — 0 3 7 12
M ountain 15 18 65 1,089 1,035 — 0 10 65 157 — 0 5 33 127
Arizona — 4 50 418 — — 0 6 43 107 — 0 4 19 60
Colorado1 12 4 31 279 399 — 0 2 2 26 — 0 2 5 55
Idaho1 N 0 0 N N — 0 1 1 — — 0 1 1 1
Montana1 1 2 28 133 188 — 0 1 1 — — 0 0 — —
Nevada1 N 0 0 N N — 0 4 12 — — 0 2 4 2
New Mexico1 2 1 4 43 95 — 0 1 4 21 — 0 0 — 4
Utah — 3 26 204 332 — 0 1 1 1 — 0 1 2 1
W yoming1 — 0 1 12 21 — 0 1 1 2 — 0 1 2 4
Pacific — 3 9 133 121 — 0 18 110 73 — 0 7 45 40
Alaska — 1 4 64 48 — 0 0 — — — 0 0 — —
California — 0 4 29 35 — 0 18 110 72 — 0 7 45 39
Hawaii — 1 4 40 38 — 0 0 — — — 0 0 — —
Oregon N 0 0 N N — 0 0 — — — 0 0 — —
Washington N 0 0 N N — 0 0 — 1 — 0 0 — 1
Territories
American Samoa N 0 0 N N — 0 0 — — — 0 0 — —
C.N.M.I. — — — — — — — — — — — — — — —
Guam — 2 4 16 28 — 0 0 — — — 0 0 — —
Puerto Rico — 4 14 179 619 — 0 0 — — — 0 0 — —
U.S. Virgin Islands — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I.: Commonwealth o f Northern Mariana Islands.
U: Unavailable. — : No reported cases. N: Not reportable. NN: Not Nationally Notifiable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.
* Case counts for reporting year 2011 are provisional and subject to  change. For further information on interpretation o f these data, see http://www.cdc.gov/osels/ph_surveillance/nndss/ 
phs/files/ProvisionalNationa%20NotifiableDiseasesSurveillanceData20100927.pdf. Data for TB are displayed in Table IV, which appears quarterly.
* Updated weekly from reports to  the Division o f Vector-Borne Infectious Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases (ArboNET Surveillance). Data for California 
serogroup, eastern equine, Powassan, St. Louis, and western equine diseases are available in Table I.
§ Not reportable in all states. Data from states where the condition is not reportable are excluded from this table, except starting in 2007 for the domestic arboviral diseases and influenza- 
associated pediatric mortality, and in 2003 for SARS-CoV. Reporting exceptions are available at http://www.cdc.gov/osels/ph_surveillance/nndss/phs/infdis.htm.
 ̂Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
MMWR /  December 23, 2011 /  Vol. 60 /  No. 50 1725
M orb id ity and M orta lity Weekly Report
TABLE III. Deaths in 122 U.S. cities,* week ending December 17, 2011 (50th week)
Reporting area









Ages >65 45-64 25-44 1-24 <1
All
Ages >65 45-64 25-44 1-24 <1
New England 498 340 111 28 13 6 36 S. A tlantic 1,137 696 303 79 32 27 56
Boston, MA 135 85 34 7 7 2 13 Atlanta, GA 154 74 60 11 5 4 6
Bridgeport, CT 28 21 5 1 — 1 1 Baltimore, MD 173 83 62 16 7 5 9
Cambridge, MA 16 10 5 — 1 — — Charlotte, NC 138 87 31 11 7 2 8
Fall River, MA 24 20 3 1 — — 4 Jacksonville, FL 21 17 3 1 — — 1
Hartford, CT 47 28 15 2 1 1 1 Miami, FL 102 70 19 9 2 2 6
Lowell, MA 20 15 5 — — — 2 Norfolk, VA 52 33 9 4 3 3 6
Lynn, MA 4 3 — — 1 — — Richmond, VA 65 36 18 7 3 1 —
New Bedford, MA 23 16 5 1 1 — 1 Savannah, GA 55 36 12 6 — 1 1
New Haven, CT 37 21 8 6 1 1 — St. Petersburg, FL 57 41 11 2 2 1 4
Providence, RI 43 30 5 7 1 — 2 Tampa, FL 203 143 47 5 1 7 11
Somerville, MA 4 3 1 — — — — Washington, D.C. 103 65 28 7 2 1 3
Springfield, MA 30 20 9 1 — — 4 W ilm ington, DE 14 11 3 — — — 1
Waterbury, CT 35 29 5 1 — — 1 E.S. Central 976 631 245 53 24 23 82
Worcester, MA 52 39 11 1 — 1 7 Birmingham, AL 193 126 47 8 4 8 15
Mid. Atlantic 2,149 1,485 495 102 39 28 81 Chattanooga, TN 118 83 26 5 3 1 7
Albany, NY 62 46 12 1 1 2 1 Knoxville, TN 110 84 24 2 — — 16
Allentown, PA 21 16 4 1 — — 3 Lexington, KY 71 46 15 7 1 2 4
Buffalo, NY 81 59 18 4 — — 4 Memphis, TN 175 95 59 10 5 6 18
Camden, NJ 22 12 7 — 2 1 — Mobile, AL 125 81 30 8 5 1 9
Elizabeth, NJ 19 9 10 — — — 2 Montgomery, AL 43 28 9 3 1 2 2
Erie, PA 53 43 8 2 — — 3 Nashville, TN 141 88 35 10 5 3 11
Jersey City, NJ 15 8 5 2 — — 1 W.S. Central 1,249 798 311 78 30 27 64
New York City, NY 1,168 811 262 53 25 17 38 Austin, TX 92 61 25 4 2 — 6
Newark, NJ 49 27 13 8 1 — 1 Baton Rouge, LA 64 44 15 4 1 — —
Paterson, NJ U U U U U U U Corpus Christi, TX 65 35 18 9 3 — 5
Philadelphia, PA 357 214 106 21 9 7 11 Dallas, TX 242 151 62 19 5 3 11
Pittsburgh, PA§ 32 24 6 1 1 — 1 El Paso, TX 83 64 13 5 1 — 3
Reading, PA 36 28 7 1 — — — Fort Worth, TX U U U U U U U
Rochester, NY 67 51 13 2 — 1 5 Houston, TX 92 53 23 4 3 8 4
Schenectady, NY 22 18 4 — — — 4 Little Rock, AR 73 47 19 3 — 3 4
Scranton, PA 28 23 2 3 — — 1 New Orleans, LA U U U U U U U
Syracuse, NY 77 61 14 2 — — 3 San Antonio, TX 288 180 77 16 10 5 20
Trenton, NJ 13 11 2 — — — 1 Shreveport, LA 114 65 32 7 3 7 1
Utica, NY 10 9 — 1 — — 1 Tulsa, OK 136 98 27 7 2 1 10
Yonkers, NY 17 15 2 — — — 1 M ountain 1,194 839 247 61 25 21 76
E.N. Central 2,198 1,454 534 113 51 46 142 Albuquerque, NM 89 64 16 3 6 — 9
Akron, OH 69 46 19 2 — 2 9 Boise, ID 56 42 11 1 1 1 4
Canton, OH 41 24 15 1 — 1 3 Colorado Springs, CO 71 50 14 2 2 3 —
Chicago, IL 245 162 52 17 12 2 22 Denver, CO 91 63 18 6 1 3 5
Cincinnati, OH 73 44 22 2 2 3 6 Las Vegas, NV 314 225 66 12 7 4 18
Cleveland, OH 247 171 52 11 8 5 15 Ogden, UT 24 16 4 4 — — 2
Columbus, OH 365 242 84 24 6 9 25 Phoenix, AZ 180 120 43 9 2 6 13
Dayton, OH 135 97 27 6 2 3 10 Pueblo, CO 48 26 16 6 — — 2
Detroit, MI 193 94 69 21 4 5 — Salt Lake City, UT 124 85 26 9 4 — 13
Evansville, IN 48 29 18 1 — — 3 Tucson, AZ 197 148 33 9 2 4 10
Fort Wayne, IN 68 46 14 5 3 — 4 Pacific 1,834 1,308 376 93 33 23 181
Gary, IN 11 7 3 — 1 — — Berkeley, CA 9 6 3 — — — 1
Grand Rapids, MI 67 54 10 1 — 2 6 Fresno, CA 132 82 29 11 7 3 23
Indianapolis, IN 188 122 50 5 5 6 12 Glendale, CA 27 21 5 1 — — 7
Lansing, MI 70 55 14 1 — — 5 Honolulu, HI 69 51 12 3 — 3 6
Milwaukee, WI 99 59 29 6 2 3 7 Long Beach, CA 70 49 14 3 3 1 9
Peoria, IL 47 32 10 2 — 3 2 Los Angeles, CA 292 208 60 16 4 4 41
Rockford, IL 42 29 10 1 2 — 2 Pasadena, CA 25 20 3 2 — — 2
South Bend, IN 42 29 8 2 1 2 4 Portland, OR 143 94 36 8 3 1 6
Toledo, OH 76 58 13 2 3 — 5 Sacramento, CA 203 146 48 6 1 2 17
Youngstown, OH 72 54 15 3 — — 2 San Diego, CA 201 149 36 11 3 2 8
W.N. Central 744 456 201 55 17 15 46 San Francisco, CA 118 86 23 8 — 1 13
Des Moines, IA 101 67 26 6 1 1 4 San Jose, CA 198 146 30 12 7 3 23
Duluth, MN 32 24 7 1 — — 1 Santa Cruz, CA 46 37 7 1 1 — 5
Kansas City, KS 24 16 6 1 1 — 1 Seattle, WA 111 73 29 5 1 3 6
Kansas City, MO 106 64 29 9 1 3 3 Spokane, WA 68 56 10 1 1 — 3
Lincoln, NE 42 30 9 2 1 — — Tacoma, WA 122 84 31 5 2 — 11
Minneapolis, MN 65 38 19 5 1 2 8 Total1 11,979 8,007 2,823 662 264 216 764
Omaha, NE 83 53 19 8 1 2 9
St. Louis, MO 151 70 55 15 8 3 10
St. Paul, MN 62 35 17 6 2 2 2
Wichita, KS 78 59 14 2 1 2 8
U: Unavailable. — : No reported cases.
* Mortality data in this table are voluntarily reported from 122 cities in the United States, most o f which have populations o f >100,000. A death is reported by the place o f its occurrence and 
by the week that the death certificate was filed. Fetal deaths are not included.
+ Pneumonia and influenza.
§ Because o f changes in reporting methods in this Pennsylvania city, these numbers are partial counts for the current week. Complete counts w ill be available in 4 to  6 weeks.
1 Total includes unknown ages.
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